

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

COLLI-PEE™, A FIRST-VOID URINE COLLECTION DEVICE FOR SELF-SAMPLING AT HOME FOR SEXUALLY TRANSMITTED INFECTIONS: EFFICACY AND ACCEPTABILITY AMONG MSM IN BELGIUM

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028145
Article Type:	Research
Date Submitted by the Author:	23-Nov-2018
Complete List of Authors:	De Baetselier, Irith; Institute of Tropical Medicine, Department of Clinical Sciences Smet, Hilde; Institute of Tropical Medicine, Department of Clinical Sciences Abdellati, Said; Institute of Tropical Medicine, Department of Clinical Sciences Cuylaerts, Vicky; Institute of Tropical Medicine, Department of Clinical Sciences De Deken, Bénédicte; Institute of Tropical Medicine, Department of Clinical Sciences Reyniers, Thijs; Institute of Tropical Medicine, Department of Public Health Vuylsteke, Bea; Institute of Tropical Medicine, Public Health Crucitti, Tania; Institute of Tropical Medicine, Department of Clinical Sciences
Keywords:	neisseria gonorrhoeae, chlamydia trachomatis, screening, urine, pre-exposure prophylaxis, MSM

SCHOLARONE™
Manuscripts

1
2
3
4 **COLLI-PEE™, A FIRST-VOID URINE COLLECTION DEVICE FOR SELF-**
5
6
7 **SAMPLING AT HOME FOR SEXUALLY TRANSMITTED INFECTIONS:**
8
9
10
11 **EFFICACY AND ACCEPTABILITY AMONG MSM IN BELGIUM**
12
13
14
15
16

17 Authors: De Baetselier Irith¹, Smet Hilde¹, Abdellati Saïd¹, De Deken Bénédicte¹, Cuylaerts Vicky¹,
18
19 Reyniers Thijs², Vuylsteke Bea², Crucitti Tania¹
20
21

22 ¹Institute of Tropical Medicine, Department of Clinical Sciences, HIV/STI Reference Laboratory,
23
24 Antwerp, Belgium
25

26
27 ²Institute of Tropical Medicine, Department of Public Health, HIV Sexual Unit, Antwerp, Belgium
28
29

30 Corresponding Author Details:
31

32
33 Irith De Baetselier MSc.
34

35 Institute of Tropical Medicine
36

37 Nationalestraat 155
38

39 2000 Antwerp
40

41 Belgium
42
43

44 Email: idebaetselier@itg.be
45

46 Telephone: +3232475444
47
48
49
50

51 Wordcount excluding title page, abstract, references, figures and tables: 3145
52
53
54
55
56
57
58
59
60

ABSTRACT:

Objectives: Pre-exposure prophylaxis (PrEP) users are screened bi-annual for Sexually Transmitted Infections (STIs). A novel device, called the Colli-Pee™, collects first-void urine in a standardized way and the collector tube can be easily delivered by regular post to a certified laboratory. The aim of the study was a one-to-one comparison between the STI test results obtained with the urine collected in the clinic, versus urine collected at home in a real-life setting by Men who have Sex with Men (MSM) in Belgium. The usability and acceptability of the Colli-Pee™ device by the users was also evaluated.

Design: A single-site nested sub-study in a prospective PrEP demonstration project (Be-PrEP-ared) among MSM in Belgium.

Participants: A total of 473 home-based samples from 213 MSM were received with a mean age of 38.5 years.

Interventions: Participants were requested to collect a urine sample at home using the Colli-Pee™ device and to send it to the laboratory via regular mail.

Primary and secondary outcome measures: The presence of *Chlamydia trachomatis* (CT), *Neisseria gonorrhoeae* (NG), *Mycoplasma genitalium* (MG) and *Trichomonas vaginalis* (TV) was determined using molecular amplification assays. Agreement between test results of samples collected at the clinic and collected at home were evaluated using Cohen's kappa statistic.

Results: *Trichomonas vaginalis* was not detected. A very good to almost perfect agreement was found for CT, NG and MG of $\kappa=0.75$; 0.87 and 0.85, respectively. Using the Colli-Pee™ device only one low positive CT and two MG infections were missed, however, three additional CT, two NG and six MG infections were detected.

Conclusions: The Colli-Pee™ device is a feasible and convenient way to collect urine at home for STI testing. This may be particularly relevant for populations that need frequent STI testing, such as PrEP users, and patients who prefer home-sampling.

Trial registration: Clinicaltrials.gov database: NCT02552914

ARTICLE SUMMARY

Strengths and limitations of this study

- The study was designed as such to provide real-world experience concerning home-based sampling for STI detection including shipment by post among PrEP users.
- Home-based and clinic-based samples were processed and analyzed using the same procedures and laboratory staff was blinded for the results of the matching sample.
- A total of 49 samples was found to be positive for an STI on 471 samples, resulting in a high prevalence of STIs: 10.4%.
- Our main limitation is that home-based samples were not taken on the same day as clinic-based sampling and participants could have become positive during that window period.
- Views and perception concerning the usability and acceptability of the device during the study were captured but not yet analyzed.

INTRODUCTION:

According to the World Health Organisation's Global Health Sector Strategy on Sexually Transmitted Infections (STIs) 2016-2021, early diagnosis and linkage to treatment are one of the key elements for preventing further transmission of STIs.[1] Currently, first-void urine is still favoured as the sample of choice for the detection of *Chlamydia trachomatis* (CT) and *Neisseria gonorrhoeae* (NG) in men, using nucleic acid amplification tests (NAATs).[2-4] In general, a regular urine container is used to collect the first-void urine sample, but the collected volume of urine is not standardized. Furthermore, this type of container is less convenient for postal delivery to the laboratory. Another sponged-based device (UriSWAB, Copan Diagnostics, Brescia, Italy) has been suggested as an alternative for postal delivery of urine. However, this device only holds 2 mL of urine and does not guarantee that only first-void urine is collected.[4,5] The CE-IVD labelled Colli-Pee™ device

1
2
3 (Novosanis, Belgium), provides a clean and standardized solution to the above-mentioned issues as
4
5 it efficiently captures first-void urine (20 mL) without interruption of the urine flow and allows the
6
7 samples to be sent by post. (Fig 1) The Colli-Pee™ device is currently used for the detection of
8
9 Human Papilloma Virus (HPV) and several urological cancers for which collection of first-void urine is
10
11 essential .[6,7] In the field of STIs, a standardized first-void urine study reported that the organism
12
13 load of *C. trachomatis* is maximal in the first 4-5 mL and that the performance of diagnostic tests
14
15 improved when using only first-void urine.[8,9]
16
17
18
19
20
21

22 Although pre-exposure prophylaxis (PrEP) is becoming crucial in HIV prevention, recent reviews of
23
24 real-world PrEP demonstration studies showed that PrEP is associated with increased diagnoses of
25
26 STIs in Men who have Sex with Men (MSM).[10,11] Consequently, current guidelines recommend a
27
28 bi-annual screening of STIs in PrEP users because of their high risk behaviour.[12,13]
29
30
31

32 In order to facilitate the patient flow during follow-up visits by PrEP users, and prompt treatment of
33
34 STIs, home-based collection of first-void urine could be sent to the laboratory by regular mail for STI
35
36 detection before the scheduled visit. STI results may then be available at the time of the physician
37
38 consultation and in the case of a detected STI also immediately treated, limiting the risk of further
39
40 transmission.
41
42
43

44 The objectives of this study were to compare the results of the molecular detection of several STIs
45
46 using the Colli-Pee™ device versus a sample obtained in the clinic, the use and acceptability of the
47
48 Colli-Pee™ device and its convenience for shipment by regular mail. To assess these objectives, a
49
50 nested sub-study was performed among MSM who participated in a Belgian PrEP demonstration
51
52 cohort. [14]
53
54
55

56 **METHODS:**

57
58
59
60

1
2
3 The evaluation was undertaken as a sub-study of Be-PrEP-ared, a PrEP demonstration study among
4
5 MSM at high risk for HIV in Belgium.
6
7

8 **The main study**

9

10 The Be-PrEP-ared project (EudraCTn^o: 5015-00005437) was a phase 3, single-site, open-label
11
12 prospective cohort study where 200 MSM at high risk of acquiring HIV were asked to participate in
13
14 the project and to take PrEP daily or event-driven. Detailed study methods are described
15
16 elsewhere.[14] Participants were tested for *Neisseria gonorrhoeae* (NG), *Chlamydia trachomatis*
17
18 (CT), *Mycoplasma genitalium* (MG) and *Trichomonas vaginalis* (TV) at baseline and every three
19
20 months. Detection of these STIs was performed at the three biological sites: urethra, anorectum and
21
22 pharynx. During each study visit, participants collected urine in two urine containers at the clinic as
23
24 per the following instructions: urinate in the first container up to the marked line at approximately
25
26 20 mL, afterwards complete the second cup with no restrictions. Urine in the first container
27
28 (hereafter the clinic-based sample) was stored refrigerated until analysis that took place within a
29
30 maximum of 48h. Urine in the second container was used to detect proteinuria.
31
32
33
34
35

36 The main study was approved by the Institutional Review Board of the Institute of Tropical Medicine
37
38 and the Ethics Committee of the Antwerp University Hospital. All participants signed an informed
39
40 consent form.
41
42
43
44
45
46

47 **Laboratory procedures**

48

49 In the first instance, CT/NG detection was performed using the Abbott Real Time (RT) CT/NG assay
50
51 (DNA extraction and sample preparation using Abbott m2000sp and the Abbott m2000rt system for
52
53 amplification and detection of CT/NG (Abbott Molecular Inc. Des Plaines, Illinois, USA)) according to
54
55 manufacturer's instructions. The remainder of the urine and DNA extracts were stored at -80 °C. In
56
57 the case of positivity, the same DNA extracts were tested by in-house real time-PCR (RT-PCR) assays
58
59
60

1
2
3 for CT and/or NG, both based on previously published primer sets.[15,16]. A sample was considered
4
5 positive when positive in both the Abbott and the in-house RT-PCR. An initial positive Abbott assay
6
7 result followed by a negative confirmatory NAAT result was defined as 'not confirmed'. Inhibition of
8
9 the NAAT according to the Abbott assay was defined as 'inhibition'.
10
11

12
13 The same DNA extracts were used for further testing. MG was detected and reported using an
14
15 accredited in-house RT-PCR that targets the pdhD-gene [17] and in addition the DiaMGTV multiplex
16
17 kit that detects MG and TV simultaneously was used for TV detection. No further confirmation of TV
18
19 took place.
20
21

22 **The Colli-Pee™ sub-study**

23
24
25 At the baseline visit of the Be-PrEP-ared study, participants were asked consent to participate in this
26
27 sub-study. After signing the informed consent form, they received a Colli-Pee™ device and a prepaid
28
29 envelope. They were instructed to collect first-void urine the next day at home using the Colli-Pee™
30
31 device (the home-based sample), to document the date and time of collection and to send the
32
33 collector tube filled with urine back to the laboratory by regular post, using the prepaid envelope.
34
35 Upon receipt in the laboratory, the urine was stored refrigerated (2-8°C) and CT, NG, MG, TV was
36
37 detected using the same NAATs within 48 hours. The urine and DNA extracts' remnants were stored
38
39 at -80°C. The quantity of human cells was measured at baseline using a human Endogenous
40
41 Retrovirus-3 (ERV-3) quantitative PCR on the paired clinic- and home-based samples.[18]
42
43
44

45
46 The lab technicians were blinded for the results obtained for the clinic-based sample. In addition, the
47
48 result of the home-based sample was not disclosed to the physician or participant.
49
50

51
52 During the next visit, which took place within 14 days after baseline, participants were asked to
53
54 complete a small survey (five questions only) on the usability and willingness to use the Colli-Pee™
55
56 device (acceptability). Two questions documenting their opinion (likes-dislikes) of the Colli-Pee™
57
58 device were open-ended.
59
60

1
2
3 At follow-up month 6 and month 18 of the study, Colli-Pee™ devices were again distributed to those
4 who agreed to participate and the survey was repeated at month 18 (results unreported).
5
6
7

8 The sub-study was approved by the Institutional Review Board of the Institute of Tropical Medicine
9 (Ref:1027/15) and has been registered in the clinicaltrials.gov database (NCT02552914).
10
11
12

13 **Patient and Public Involvement**

14
15
16 Patients were not involved in the colli-pee™ substudy. Patients were not invited to comment on the
17 study design and were not consulted to develop patient relevant outcomes or interpret the results.
18
19

20 Patients were not invited to contribute to the writing or editing of this document for readability or
21 accuracy.
22
23
24
25

26 **Statistical analysis**

27
28 The agreement of the results of the molecular assays using each of the two sampling methods was
29 assessed by the use of Cohen's kappa statistic. Samples that were not confirmed were coded as
30 negative samples for the calculation of the agreement. The agreement of concentration of human
31 DNA in both sampling methods was assessed by using a t-test. A p-value of <0.05 was considered
32 statistically significant. Both analyses were performed using STATA version 15.0 (StataCorp LP,
33 College Station, TX, USA).
34
35
36
37
38
39
40
41

42 A descriptive analysis was made of the results of the self-administered questionnaire on the usability
43 of the Colli-Pee™ device.
44
45
46
47

48 **RESULTS**

49 **Demographics**

50
51
52 The main study took place at the Institute of Tropical Medicine, Antwerp, Belgium from Sep 2015
53 until May 2018. Of the 219 participants who were screened for eligibility into the main study, six
54 participants did not consent to the Colli-Pee™ sub-study. All participants who consented to the sub-
55
56
57
58
59
60

study were MSM and three identified themselves as transwomen.[19] The mean age of the participants was 38.5 years (Interquartile Range 32-44). A total of 473 home-based samples from 213 participants were received. Two home-based samples could not be linked to the corresponding clinic-based sample and were therefore excluded, bringing the total number to 471. As shown in Table 1, the number of home-based samples received at the laboratory declined over time.

Kind Of Visit	Clinic based	Home Based (% home-based samples received)
Screening	218	187 (85.8%)
Month 6	191	152 (79.6%)
Month 18	179	132 (73.7%)

Table 1: Number of clinic and home-based samples received during the study

Although the participants were instructed to report the urine collection date and hour on the collection device, only 72.8% (343/471) were labelled with collection date. Most of the home-based samples (79.6%) were taken within two days after the clinic-based sample and 3.8% were taken after 20 days (13/343) (median one day; min-max: 0-70 days). The median time between the collection of the home-based sample and its reception at the laboratory after postal return was five days (min-max: 0-27 days) and 69.6% arrived at the laboratory within those five days.

Comparison of weight and concentration of human material between both sampling methods.

A total of 455 home-based and 423 clinic-based samples were weighed. The mean net weight of the home-based sample was $19.68\text{g} \pm 2.14\text{g}$ (95%CI: 19.5g-19.9g and min-max: 6.81g-39.47g) vs $22.87\text{g} \pm 13.64\text{g}$ (95%CI: 21.6g-24.2g and min-max: 2.88g - 86.23g) for the clinic-based sample.

The quantity of human cells was analysed at baseline only (n=187). In a total of five home-based and one clinic-based sample ERV could not be detected and these samples were considered as lacking human material. After removal of the paired samples lacking ERV or containing inhibitors, 182 observations could be paired. The mean quantity of the clinic-based sample was 11.3×10^3 cells/PCR (95%CI: 7.4 - 15.2×10^3) and for the home-based sample 14.2×10^3 cells/PCR (95% CI: 6.8- 21.5×10^3) (p>0.05).

STI results and agreement

Of the 471 home-based samples with a matching visit, six home-based and one clinic-based sample gave inhibition and were excluded from the analysis (n=464). The results are shown in Table 2.

STI	Home-based urine result	Clinic-based urine results		
		Negative	Positive	Total
<i>Chlamydia trachomatis</i> (non-LGV)	Negative	454*	1	455
	Positive	3	6	9
	Total	457	7	464
<i>Neisseria gonorrhoeae</i>	Negative	455	0	455
	Positive	2	7	9
	Total	457	7	464
<i>Mycoplasma genitalium</i>	Negative	431	2	433
	Positive	6	25	31
	Total	437	27	464
<i>Trichomonas vaginalis</i>	Negative	464	0	464
	Positive	0	0	0
	Total	464	0	464

Table 2: STI results of the home-based and clinic-based urine samples

* Two result were not-confirmed in the clinic-based sample

Trichomonas vaginalis was not detected. Cohen's kappa-agreement for CT/NG/MG is 0.75; 0.87 and 0.85, respectively, which indicates substantial agreement for *Chlamydia trachomatis* and almost perfect agreement for the other two STIs.

Tables 3 and 4 show the discordant results. For some of the home-based samples the date of collection was unknown so the time between the clinic visit and time of reception at the laboratory is depicted here. A delta-cycle (DC) value of the Abbott assay of less than two indicates a low positive infection.

STI	DC value CT/NG Abbott assay	Ct value in- house RT-PCR for CT or NG*	Ct-value S- DiagMGTV RT-PCR	Days between collection	Days of transport
CT	1.49	33.19	NA	0	2
MG	NA	32.20	Neg	3	4
MG	NA	32.04	37.44	0	8

Table 3: STI infections that were not detected in home-based urine samples

*: a different in-house RT-PCR assay was used for CT and NG

DC = delta cycle; Ct = Cycle threshold; NA = not applicable; Max = days between clinic visit and reception of the home-based sample at the laboratory

STI	DC value CT/NG Abbott assay	Ct value in- house RT-PCR for CT or NG*	Ct-value S- DiagMGTV RT-PCR	Days between collection	Days of transport
CT	3.99	34.26	NA	1	2
CT	2.68	35.31	NA	1	6
CT	0.27	36.06	NA	6	4

STI	DC value CT/NG Abbott assay	Ct value in- house RT-PCR for CT or NG*	Ct-value S- DiagMGTV RT-PCR	Days between collection	Days of transport
NG	2.93	37.58	NA	8	4
NG	10.08	25.26	NA	2	6
MG	NA	31.28	Neg	Max 6	Max 6
MG	NA	31.96	40.51	1	2
MG	NA	28.66	34.67	Max 3	Max 3
MG	NA	34.58	38.50	9	4
MG	NA	34.23	Neg	1	5
MG	NA	32.04	38.14	Max 3	Max 3

Table 4: STI infections that were additionally detected in home-based urine samples

*: a different in-house RT-PCR assay was used for CT and NG

DC = delta cycle; Ct = Cycle threshold; NA = not applicable; Max = days between clinic visit and reception of the home-based sample at the laboratory

Acceptability and usability of the Colli-Pee™ device

A total of 164 participants provided feedback regarding the use of the Colli-Pee™ device at baseline. On a scale of one to five, 87.8% found that the Colli-Pee™ device was easy to very easy to use. Instructions on how to send the Colli-Pee™ device were found to be easy by 90.2% of the participants. Four participants found the Colli-Pee™ difficult to use (2.4%) and four other participants found it difficult to follow the instructions (2.4%). Likes from participants were: the ease of use (54.9%), no interruption of the urine flow (15.9%), hygienic (11.6%) and privacy of the home-based sample collection (11.0%); the dislikes were: nothing (47.0%), not being recyclable (14.6%), not hygienic (10.4%) and being too large (6.1%).

To the question of whether they would order an online STI test, 89.0% answered positively (146/164) and 91.1% (133/146) of those individuals would use the Colli-Pee™ device in that case. Six

1
2
3 participants (4.1%) would not want to use the Colli-Pee™ device when ordering an online STI test.
4
5 Participants were also asked how much they would pay for an online STI test with self-sampling.
6
7 Price indications ranged from 0€ (10 participants) to 60€. Most of the participants (89/164) were
8
9 willing to pay 10-20€.
10
11
12
13
14
15

16 DISCUSSION

17
18
19 Many studies have reported on male self-collected urine versus urethra clinician-collected sampling
20
21 for STI screening , but ‘real-world’ studies, including sending of home-based urine samples for STI
22
23 detection in men by post, are sparse.[4,5,20,21] In this study, we showed that the Colli-Pee™
24
25 collection device is a valuable and reliable method for collecting first-void urine for STI detection in
26
27 MSM in Belgium, and that the collector can be shipped by regular post. Compared to the clinic-based
28
29 sample, a total of three STIs (one CT and two MG infections) were not detected in the home-based
30
31 sample. However, 11 additional infections were found in home-based samples collected with the
32
33 Colli-Pee™ device (3 CT, 2 NG and 6 MG infections). This high number of additional STIs could be
34
35 explained by the fact that first-void urine contains more DNA/RNA than mid-stream and, as a
36
37 consequence, should still be used for STI detection.[9] However, the fact that participants could
38
39 become positive during the time in between sampling points is one of our main limitations and
40
41 cannot be ignored. Nevertheless, the most important observation is that only one Chlamydia
42
43 positive result was missed. The DC value of the Abbott assay performed on that clinic-based sample
44
45 highlighted the low bacterial load of that infection; in addition, transportation at room temperature
46
47 for two days could have induced DNA degradation.
48
49
50
51
52

53 The World Health Organisation (WHO) underlines the importance of integrating point-of-care assays
54
55 (POCTs) including innovative delivery options such as self-testing. [22] Unfortunately, to our
56
57 knowledge, current commercial POCTs for the most important STIs such as *Chlamydia trachomatis*
58
59
60

1
2
3 and *Neisseria gonorrhoeae* are still of sub-optimal quality and do not meet the ASSURED criteria that
4 were developed by the WHO STI Diagnostics Initiative.[22–25] A solution to the unavailability of
5 qualitative POCTs could be internet-accessed STI testing (e-STI testing) which is increasingly available
6 as an alternative to clinic testing all over the world.[26] E-STI testing includes postal self-sampling
7 test kits that are sent to a certified laboratory and web-based delivery of test results. Swab2Know,
8 an online HIV testing project confirmed that e-HIV testing is acceptable and feasible among MSM in
9 Belgium. [27] Commercial online self-sampling services for STIs are now emerging over the internet,
10 but evaluation of these services is lacking.

11
12 The present study is, however, subject to several limitations. Firstly, we could only enrol Be-PrEP-
13 ared participants and the participation level seriously declined during the study. As a result, our
14 number of CT/NG positives is quite low, which precludes firm conclusions. Secondly, as mentioned
15 above, home-based samples were not taken on the same day as clinic-based sampling and
16 participants could have become positive during that window period. We also do not know whether
17 participants had urinated one hour prior to collection. However, recent data show that the time
18 between micturitions is not crucial for the detection of Chlamydia in men.[28] Finally, reporting bias
19 is also not to be excluded. Not all participants who used a Colli-Pee™ device completed the survey,
20 the additional questions were included at the end of the lengthy main questionnaire of the Be-PrEP-
21 ared study.

22
23 Besides PrEP users, e-STI testing has the potential to reach those who are most in need and a recent
24 study showed that some higher-risk groups, such as MSM, were more likely to use online services
25 [26,29]. Many studies have shown that home-based sampling is well accepted and, in fact, is the
26 preferred approach in these groups for STIs. Reasons for choosing home-based sampling were
27 shorter waiting times for results, convenience and less embarrassment. [30] Participants views
28 regarding ordering an online STI test in this study were very positive, 89% would like to order such a
29 kit. The Colli-Pee™ device was also found to be easy (90.2%) and although hygiene was one of the
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 likes, it also appeared in the dislikes, probably because the need to detach the collector manually
4
5 can cause leakage of urine. Participants were also concerned regarding possible ecological
6
7 consequences, although the plastic material is recyclable and can be incinerated into energy.
8
9

10 We demonstrated that postal delivery of home-based collected urine does not influence STI
11
12 detection and can be used among PrEP users. Subsequently, PrEP users will be able to send first-void
13
14 urine to the laboratory with the Colli-Pee™ device one to two weeks before their routine PrEP follow
15
16 up visit. Results can then be discussed during the physician consultation and followed by treatment
17
18 and future antimicrobial testing if applicable, decreasing the number of physician visits. Decreasing
19
20 the number of face-to-face visits will lower the burden on staff workload and healthcare resources.
21
22 However, future economic evaluations will need to be conducted to prove this statement. E-STI
23
24 testing could be a promising approach in Belgium to reach patients in hard-to-reach populations and
25
26 research on this topic should be stimulated. Therefore, future studies to study the acceptability and
27
28 impact of postal shipment of home-collected material on the performance of STI assays requires
29
30 additional assessment.
31
32
33
34
35
36
37
38

39 Figure legend: Fig 1: The Colli-Pee™ device instructions for use.
40
41

42 **ACKNOWLEDGEMENTS**

43
44
45 We would like to thank all the participants of the Be-PrEP-ared study who participated in this small
46
47 study. We also would like to thank Be-PrEP-ared study group but especially Maureen Aerts who was
48
49 crucial in the participation level of this study.
50
51

52 **COMPETING INTERESTS STATEMENT**

53
54
55 The authors have no competing interests to declare.
56
57
58
59
60

FUNDING STATEMENT

This work was supported by Novosanis who provided the Colli-Pee™ devices and partially paid for the analyses performed on the home-based samples. In addition, a grant was obtained from the Flemish Agency for Innovation and Entrepreneurship to conduct the Be-PrEP-ared study.

DATASHARING STATEMENT

The data will be made publicly available except for the use and acceptability data as these will be retained at the Institute of Tropical Medicine (ITM), Antwerp due to ethical and privacy concerns. According to the ITM research data sharing policy, only fully anonymised data can be shared publicly. The data can however be made available after approval of a motivated and written request to the ITM at ITMresearchdataaccess@itg.be. The ITM data access committee will verify if the dataset is suitable for obtaining the study objective and assure that confidentiality and ethical requirements are in place.

CONTRIBUTORSHIP STATEMENT

IDB, TC, and BV designed the study. TR designed the acceptability survey. IDB performed the statistical analysis and wrote the first draft of the manuscript. HS, BDD, VC, SA performed testing. All authors read the final version of the manuscript and provided comments.

REFERENCES

- 1 WHO. Global Health Sector Strategy on Sexually Transmitted Infections 2016-2021. *World Heal Organ* 2016;**1**:63. doi:10.1055/s-2007-970201.
- 2 Lanjouw E, Ouburg S, de Vries H, *et al.* 2015 European guideline on the management of *Chlamydia trachomatis* infections. *Int J STD AIDS* 2016;**27**:333–48. doi:10.1177/0956462415618837

- 1
2
3 3 Bignell C, Unemo M, Radcliffe K, *et al.* 2012 European guideline on the diagnosis and
4 treatment of gonorrhoea in adults. *Int J STD AIDS* 2013;**24**:85–92.
5
6 doi:10.1177/0956462412472837
7
8
9
10 4 Lunny C, Taylor D, Hoang L, *et al.* Self-Collected versus Clinician-Collected Sampling for
11 Chlamydia and Gonorrhoea Screening: A Systemic Review and Meta-Analysis. *PLoS One*
12 2015;**10**:e0132776. doi:10.1371/journal.pone.0132776
13
14
15
16
17 5 McNicol J, Debattista J. Use of the UriSwab collection device for testing of *Chlamydia*
18 *trachomatis* and *Neisseria gonorrhoeae* : implications for a postal testing service. *Int J STD*
19 *AIDS* 2013;**24**:477–80. doi:10.1177/0956462412472834
20
21
22
23
24
25 6 Vorsters A, Van den Bergh J, Micalessi I, *et al.* Optimization of HPV DNA detection in urine by
26 improving collection, storage, and extraction. *Eur J Clin Microbiol Infect Dis* 2014;**33**:2005–14.
27
28 doi:10.1007/s10096-014-2147-2
29
30
31
32 7 Theodorescu D, Schiffer E, Bauer HW, *et al.* Discovery and validation of urinary biomarkers for
33 prostate cancer. *Proteomics Clin Appl* 2008;**2**:556–70. doi:10.1002/prca.200780082
34
35
36
37 8 Wisniewski CA, White JA, Michel C-EC, *et al.* Optimal method of collection of first-void urine
38 for diagnosis of *Chlamydia trachomatis* infection in men. *J Clin Microbiol* 2008;**46**:1466–9.
39
40
41
42
43
44
45 9 Johnson DJ, Calderaro AC, Roberts KA. Variation in Nuclear DNA Concentrations During
46 Urination. *J Forensic Sci* 2007;**52**:110–3. doi:10.1111/j.1556-4029.2006.00329.x
47
48
49
50 10 Traeger MW, Schroeder SE, Wright EJ, *et al.* Effects of Pre-exposure Prophylaxis for the
51 Prevention of Human Immunodeficiency Virus Infection on Sexual Risk Behavior in Men Who
52 Have Sex With Men: A Systematic Review and Meta-analysis. *Clin Infect Dis* Published Online
53
54
55
56
57
58
59
60 11 Kojima N, Davey DJ, Klausner JD. Pre-exposure prophylaxis for human immunodeficiency

- 1
2
3 virus and sexually transmitted infection acquisition among men who have sex with men. *AIDS*
4
5 Published Online First: 2016. doi:10.1097/QAD.0000000000001185
6
7
8
9 12 Salazar NAMEJ. EACS HIV guidelines 8.1. 2016.
10
11 13 WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection. *Geneva*
12
13 *World Heal Organ* Published Online First: 2017.[http://www.who.int/hiv/pub/prep/prep-](http://www.who.int/hiv/pub/prep/prep-implementation-tool/en/)
14
15 [implementation-tool/en/](http://www.who.int/hiv/pub/prep/prep-implementation-tool/en/) (accessed 21 Aug 2018).
16
17
18
19 14 De Baetselier I, Reyniers T, Nöstlinger C, *et al.* Pre-Exposure Prophylaxis (PrEP) as an
20
21 Additional Tool for HIV Prevention Among Men Who Have Sex With Men in Belgium: The Be-
22
23 PrEP-ared Study Protocol. *JMIR Res Protoc* 2017;**6**:e11. doi:10.2196/resprot.6767
24
25
26 15 Chen C-Y, Chi KH, Alexander S, *et al.* A real-time quadriplex PCR assay for the diagnosis of
27
28 rectal lymphogranuloma venereum and non-lymphogranuloma venereum Chlamydia
29
30 trachomatis infections. *Sex Transm Infect* 2008;**84**:273–6. doi:10.1136/sti.2007.029058
31
32
33 16 Hopkins MJ, Ashton LJ, Alloba F, *et al.* Validation of a laboratory-developed real-time PCR
34
35 protocol for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine. *Sex*
36
37 *Transm Infect* 2010;**86**:207–11. doi:10.1136/sti.2009.040634
38
39
40 17 Müller EE, Venter JME, Magooa MP, *et al.* Development of a rotor-gene real-time PCR assay
41
42 for the detection and quantification of Mycoplasma genitalium. *J Microbiol Methods*
43
44 2012;**88**:311–5. doi:10.1016/j.mimet.2011.12.017
45
46
47
48 18 Yuan CC, Miley W, Waters D. A quantification of human cells using an ERV-3 real time PCR
49
50 assay. *J Virol Methods* 2001;**91**:109–17.
51
52
53 19 Reyniers T, Nöstlinger C, Laga M, *et al.* Choosing between daily and event-driven Pre-
54
55 Exposure Prophylaxis: results of a Belgian PrEP demonstration project Conflict of Interest and
56
57 Source of Funding: A grant was obtained from the Flemish Agency for. *JAIDS J Acquir Immune*
58
59 *Defic Syndr Publ Ahead Print* doi:10.1097/QAI.0000000000001791
60

- 1
2
3 20 Morré SA, van Valkengoed IG, de Jong A, *et al.* Mailed, home-obtained urine specimens: a
4 reliable screening approach for detecting asymptomatic *Chlamydia trachomatis* infections. *J*
5 *Clin Microbiol* 1999;**37**:976–80.<http://www.ncbi.nlm.nih.gov/pubmed/10074512> (accessed
6 21 Aug 2018).
7
8
9
10
11
12 21 Fajardo-Bernal L, Aponte-Gonzalez J, Vigil P, *et al.* Home-based versus clinic-based specimen
13 collection in the management of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*
14 infections. *Cochrane Database Syst Rev* 2015;:CD011317.
15 doi:10.1002/14651858.CD011317.pub2
16
17
18
19
20
21
22 22 Toskin I, Blondeel K, Peeling RW, *et al.* Advancing point of care diagnostics for the control and
23 prevention of STIs: the way forward. *Sex Transm Infect* 2017;**93**:S81–8. doi:10.1136/sextrans-
24 2016-053073
25
26
27
28
29
30 23 De Baetselier I, Mwambarangwe L, Cuylaerts V, *et al.* Evaluation of an enzymatic *Chlamydia*
31 *trachomatis* point-of-care rapid assay in Rwanda: the BioChekSwab Rapid Test. *Sex Transm*
32 *Infect* Published Online First: 16 October 2015. doi:10.1136/sextrans-2015-052202
33
34
35
36
37 24 Peeling RW, Holmes KK, Mabey D, *et al.* Rapid tests for sexually transmitted infections (STIs):
38 the way forward. *Sex Transm Infect* 2006;**82**:v1–6. doi:10.1136/sti.2006.024265
39
40
41
42 25 European Centre for Disease Prevention and Control. Novel approaches to testing for sexually
43 transmitted infections, including HIV and hepatitis B and C in Europe. Stockholm: 2012.
44 doi:10.2900/6481
45
46
47
48
49 26 Wilson E, Free C, Morris TP, *et al.* Internet-accessed sexually transmitted infection (e-STI)
50 testing and results service: A randomised, single-blind, controlled trial. *PLOS Med*
51 2017;**14**:e1002479. doi:10.1371/journal.pmed.1002479
52
53
54
55
56
57 27 Platteau T, Fransen K, Apers L, *et al.* Swab2know: An HIV-Testing Strategy Using Oral Fluid
58 Samples and Online Communication of Test Results for Men Who Have Sex With Men in
59
60

- 1
2
3 Belgium. *J Med Internet Res* 2015;**17**:e213. doi:10.2196/jmir.4384
4
5
6 28 Mathew T, O'Mahony C, Mallinson H. Shortening the voiding interval for men having
7
8 chlamydia nucleic acid amplification tests. *Int J STD AIDS* 2009;**20**:752–3.
9
10 doi:10.1258/ijisa.2009.009225
11
12
13 29 Barnard S, Free C, Bakolis I, *et al*. Comparing the characteristics of users of an online service
14
15 for STI self-sampling with clinic service users: a cross-sectional analysis. *Sex Transm Infect*
16
17 2018;;sextrans-2017-053302. doi:10.1136/sextrans-2017-053302
18
19
20
21 30 Paudyal P, Llewellyn C, Lau J, *et al*. Obtaining self-samples to diagnose curable sexually
22
23 transmitted infections: a systematic review of patients' experiences. *PLoS One*
24
25 2015;**10**:e0124310. doi:10.1371/journal.pone.0124310
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



55x26mm (220 x 220 DPI)

Section & Topic	No	Item	Reported on page #
TITLE OR ABSTRACT			
	1	Identification as a study of diagnostic accuracy using at least one measure of accuracy (such as sensitivity, specificity, predictive values, or AUC)	2 (agreement was used as this is not a diagnostic study)
ABSTRACT			
	2	Structured summary of study design, methods, results, and conclusions (for specific guidance, see STARD for Abstracts)	2
INTRODUCTION			
	3	Scientific and clinical background, including the intended use and clinical role of the index test	3-4
	4	Study objectives and hypotheses	4
METHODS			
<i>Study design</i>	5	Whether data collection was planned before the index test and reference standard were performed (prospective study) or after (retrospective study)	5
<i>Participants</i>	6	Eligibility criteria	5
	7	On what basis potentially eligible participants were identified (such as symptoms, results from previous tests, inclusion in registry)	5-6
	8	Where and when potentially eligible participants were identified (setting, location and dates)	5
	9	Whether participants formed a consecutive, random or convenience series	5-6
<i>Test methods</i>	10a	Index test, in sufficient detail to allow replication	Not applicable same assay was used on both samples (but different kind of sample)
	10b	Reference standard, in sufficient detail to allow replication	Not applicable same assay was used on both samples (but different kind of sample)
	11	Rationale for choosing the reference standard (if alternatives exist)	Not applicable same assay was used on both samples (but different kind of sample)
	12a	Definition of and rationale for test positivity cut-offs or result categories of the index test, distinguishing pre-specified from exploratory	5-6
	12b	Definition of and rationale for test positivity cut-offs or result categories of the reference standard, distinguishing pre-specified from exploratory	5-6
	13a	Whether clinical information and reference standard results were available to the performers/readers of the index test	6
	13b	Whether clinical information and index test results were available to the assessors of the reference standard	6
<i>Analysis</i>	14	Methods for estimating or comparing measures of diagnostic accuracy	7
	15	How indeterminate index test or reference standard results were handled	6
	16	How missing data on the index test and reference standard were handled	Not applicable
	17	Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from exploratory	Not applicable
	18	Intended sample size and how it was determined	Not applicable
RESULTS			
<i>Participants</i>	19	Flow of participants, using a diagram	We did not include of flow of participants, however this has been discussed in the text p7-8

1		20	Baseline demographic and clinical characteristics of participants	7-8
2		21a	Distribution of severity of disease in those with the target condition	Not applicable
3		21b	Distribution of alternative diagnoses in those without the target condition	Not applicable
4		22	Time interval and any clinical interventions between index test and reference standard	8
5	<i>Test results</i>	23	Cross tabulation of the index test results (or their distribution) by the results of the reference standard	8
6		24	Estimates of diagnostic accuracy and their precision (such as 95% confidence intervals)	Cohen's kappa agreement was used p9
7		25	Any adverse events from performing the index test or the reference standard	Not applicable
8				
9				
10		25	Any adverse events from performing the index test or the reference standard	Not applicable
11	DISCUSSION			
12		26	Study limitations, including sources of potential bias, statistical uncertainty, and generalisability	13
13		27	Implications for practice, including the intended use and clinical role of the index test	13-14
14				
15	OTHER INFORMATION			
16				
17		28	Registration number and name of registry	6
18		29	Where the full study protocol can be accessed	Will be added as appendix
19		30	Sources of funding and other support; role of funders	15
20				
21				
22				
23				
24				
25				
26				
27				
28				
29				
30				
31				
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

STARD 2015

AIM

STARD stands for “Standards for Reporting Diagnostic accuracy studies”. This list of items was developed to contribute to the completeness and transparency of reporting of diagnostic accuracy studies. Authors can use the list to write informative study reports. Editors and peer-reviewers can use it to evaluate whether the information has been included in manuscripts submitted for publication.

EXPLANATION

A **diagnostic accuracy study** evaluates the ability of one or more medical tests to correctly classify study participants as having a **target condition**. This can be a disease, a disease stage, response or benefit from therapy, or an event or condition in the future. A medical test can be an imaging procedure, a laboratory test, elements from history and physical examination, a combination of these, or any other method for collecting information about the current health status of a patient.

The test whose accuracy is evaluated is called **index test**. A study can evaluate the accuracy of one or more index tests. Evaluating the ability of a medical test to correctly classify patients is typically done by comparing the distribution of the index test results with those of the **reference standard**. The reference standard is the best available method for establishing the presence or absence of the target condition. An accuracy study can rely on one or more reference standards.

If test results are categorized as either positive or negative, the cross tabulation of the index test results against those of the reference standard can be used to estimate the **sensitivity** of the index test (the proportion of participants *with* the target condition who have a positive index test), and its **specificity** (the proportion *without* the target condition who have a negative index test). From this cross tabulation (sometimes referred to as the contingency or “2x2” table), several other accuracy statistics can be estimated, such as the positive and negative **predictive values** of the test. Confidence intervals around estimates of accuracy can then be calculated to quantify the statistical **precision** of the measurements.

If the index test results can take more than two values, categorization of test results as positive or negative requires a **test positivity cut-off**. When multiple such cut-offs can be defined, authors can report a receiver operating characteristic (ROC) curve which graphically represents the combination of sensitivity and specificity for each possible test positivity cut-off. The **area under the ROC curve** informs in a single numerical value about the overall diagnostic accuracy of the index test.

The **intended use** of a medical test can be diagnosis, screening, staging, monitoring, surveillance, prediction or prognosis. The **clinical role** of a test explains its position relative to existing tests in the clinical pathway. A replacement test, for example, replaces an existing test. A triage test is used before an existing test; an add-on test is used after an existing test.

Besides diagnostic accuracy, several other outcomes and statistics may be relevant in the evaluation of medical tests. Medical tests can also be used to classify patients for purposes other than diagnosis, such as staging or prognosis. The STARD list was not explicitly developed for these other outcomes, statistics, and study types, although most STARD items would still apply.

DEVELOPMENT

This STARD list was released in 2015. The 30 items were identified by an international expert group of methodologists, researchers, and editors. The guiding principle in the development of STARD was to select items that, when reported, would help readers to judge the potential for bias in the study, to appraise the applicability of the study findings and the validity of conclusions and recommendations. The list represents an update of the first version, which was published in 2003.

More information can be found on <http://www.equator-network.org/reporting-guidelines/stard>.



BMJ Open

EVALUATION OF THE "COLLI-PEE™", A FIRST-VOID URINE COLLECTION DEVICE FOR SELF-SAMPLING AT HOME FOR THE DETECTION OF SEXUALLY TRANSMITTED INFECTIONS, VERSUS A ROUTINE CLINIC BASED URINE COLLECTION IN A ONE-TO-ONE COMPARISON STUDY DESIGN: EFFICACY AND ACCEPTABILITY AMONG MSM IN BELGIUM

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028145.R1
Article Type:	Research
Date Submitted by the Author:	12-Feb-2019
Complete List of Authors:	De Baetselier, Irith; Institute of Tropical Medicine, Department of Clinical Sciences Smet, Hilde; Institute of Tropical Medicine, Department of Clinical Sciences Abdellati, Said; Institute of Tropical Medicine, Department of Clinical Sciences De Deken, Bénédicte; Institute of Tropical Medicine, Department of Clinical Sciences Cuylaerts, Vicky; Institute of Tropical Medicine, Department of Clinical Sciences Reyniers, Thijs; Institute of Tropical Medicine, Department of Public Health Vuylsteke, Bea; Institute of Tropical Medicine, Public Health Crucitti, Tania; Institute of Tropical Medicine, Department of Clinical Sciences
Primary Subject Heading:	Sexual health
Secondary Subject Heading:	Diagnostics
Keywords:	neisseria gonorrhoeae, chlamydia trachomatis, screening, urine, pre-exposure prophylaxis, MSM

SCHOLARONE™
Manuscripts

1
2
3
4
5 **EVALUATION OF THE “COLLI-PEE™”, A FIRST-VOID URINE**
6
7
8
9
10 **COLLECTION DEVICE FOR SELF-SAMPLING AT HOME**
11
12
13
14 **FOR THE DETECTION OF SEXUALLY TRANSMITTED**
15
16
17
18 **INFECTIONS, VERSUS A ROUTINE CLINIC BASED URINE**
19
20
21
22
23 **COLLECTION IN A ONE-TO-ONE COMPARISON STUDY**
24
25
26
27
28 **DESIGN: EFFICACY AND ACCEPTABILITY AMONG MSM IN**
29
30
31
32 **BELGIUM**

33
34
35
36
37
38
39 Authors: De Baetselier Irith¹, Smet Hilde¹, Abdellati Saïd¹, De Deken Bénédicte¹, Cuylaerts Vicky¹,
40
41 Reyniers Thijs², Vuylsteke Bea², Crucitti Tania¹

42
43
44
45 ¹Institute of Tropical Medicine, Department of Clinical Sciences, HIV/STI Reference Laboratory,
46
47 Antwerp, Belgium

48
49
50 ²Institute of Tropical Medicine, Department of Public Health, HIV Sexual Unit, Antwerp, Belgium

51
52
53 Corresponding Author Details:

54
55
56 Irith De Baetselier MSc.

57
58
59 Institute of Tropical Medicine

60
Nationalestraat 155

1
2
3 2000 Antwerp
4

5 Belgium
6

7 Email: idebaetselier@itg.be
8

9
10 Telephone: +3232475444
11

12 Wordcount excluding title page, abstract, references, figures and tables: 3332
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ABSTRACT:

Objectives: Pre-exposure prophylaxis (PrEP) users are screened bi-annual for Sexually Transmitted Infections (STIs). A novel device, called the Colli-Pee™, collects first-void urine in a standardized way and the collector tube can be easily delivered by regular post to a certified laboratory. The aim of the study was a one-to-one comparison between the STI test results obtained with the urine collected in the clinic, versus urine collected at home in a real-life setting by Men who have Sex with Men (MSM) in Belgium. The user-friendliness and acceptability of the Colli-Pee™ device by the users was also evaluated.

Design: A single-site nested sub-study in a prospective PrEP demonstration project (Be-PrEP-ared) among MSM in Belgium.

Participants: A total of 473 home-based samples from 213 MSM were received with a mean age of 38.5 years.

Interventions: Participants were requested to collect a urine sample at home using the Colli-Pee™ device and to send it to the laboratory via regular mail.

Primary and secondary outcome measures: The presence of *Chlamydia trachomatis* (CT), *Neisseria gonorrhoeae* (NG), *Mycoplasma genitalium* (MG) and *Trichomonas vaginalis* (TV) was determined using molecular amplification assays. Agreement between test results of samples collected at the clinic and collected at home were evaluated using Cohen's kappa statistic. Results: *Trichomonas vaginalis* was not detected. A very good to almost perfect agreement was found for CT, NG and MG of $\kappa=0.75$; 0.87 and 0.85, respectively. Using the Colli-Pee™ device only one low positive CT and two MG infections were missed, however, three additional CT, two NG and six MG infections were detected.

1
2
3 Conclusions: The Colli-Pee™ device is a feasible and convenient way to collect urine at home for STI
4 testing. This may be particularly relevant for populations that need frequent STI testing, such as PrEP
5 users, and patients who prefer home-sampling.
6
7
8
9

10 Trial registration: Clinicaltrials.gov database: NCT02552914
11
12

13 14 15 ARTICLE SUMMARY

16 17 18 19 Strengths and limitations of this study

- 20 • The study was designed as such to provide real-world experience concerning home-based
21 sampling for STI detection including shipment by post among PrEP users.
22
- 23 • Home-based and clinic-based samples were processed and analyzed using the same
24 procedures and laboratory staff was blinded for the results of the matching sample.
25
- 26 • A total of 49 samples was found to be positive for an STI on 471 samples, resulting in a high
27 prevalence of STIs: 10.4%.
28
- 29 • Our main limitation is that home-based samples were not taken on the same day as clinic-
30 based sampling and participants could have become positive during that window period.
31
- 32 • Another limitation of the study is that the temperature during transportation of home-based
33 samples to the clinic was not monitored. Large temperature variations could have an impact
34 on the quality of the samples.
35
36
37
38
39
40
41
42
43
44
45
46

47 48 49 INTRODUCTION:

50
51 According to the World Health Organisation's Global Health Sector Strategy on Sexually Transmitted
52 Infections (STIs) 2016-2021, early diagnosis and linkage to treatment are one of the key elements for
53 preventing further transmission of STIs.[1] Currently, first-void urine is still favoured as the sample of
54 choice for the detection of *Chlamydia trachomatis* (CT) and *Neisseria gonorrhoeae* (NG) in men, using
55 nucleic acid amplification tests (NAATs).[2–4] In general, a regular urine container is used to collect
56
57
58
59
60

1
2
3 the first-void urine sample, but the collected volume of urine is not standardized. Furthermore, this
4
5 type of container is less convenient for postal delivery to the laboratory. Another sponged-based
6
7 device (UriSWAB, Copan Diagnostics, Brescia, Italy) has been suggested as an alternative for postal
8
9 delivery of urine. However, this device only holds 2 mL of urine and does not guarantee that only first-
10
11 void urine is collected.[4,5] The CE-IVD labelled Colli-Pee™ device (Novosanis, Belgium), provides a
12
13 clean and standardized solution to the above-mentioned issues as it efficiently captures first-void
14
15 urine (20 mL) without interruption of the urine flow and allows the samples to be sent by post. (Fig 1)
16
17 The Colli-Pee™ device is currently used for the detection of Human Papilloma Virus (HPV) and several
18
19 urological cancers for which collection of first-void urine is essential.[6,7] In the field of STIs, a
20
21 standardized first-void urine study reported that the organism load of *C. trachomatis* is maximal in the
22
23 first 4-5 mL and that the performance of diagnostic tests improved when using only first-void
24
25 urine.[8,9]
26
27
28
29
30
31
32
33

34 Although pre-exposure prophylaxis (PrEP) is becoming crucial in HIV prevention, recent reviews of
35
36 real-world PrEP demonstration studies showed that PrEP is associated with increased diagnoses of
37
38 STIs in Men who have Sex with Men (MSM).[10,11] Consequently, current guidelines recommend a
39
40 bi-annual screening of STIs in PrEP users because of their high risk behaviour.[12,13]
41
42

43 In order to facilitate the patient flow during follow-up visits by PrEP users, and prompt treatment of
44
45 STIs, home-based collection of first-void urine could be sent to the laboratory by regular mail for STI
46
47 detection before the scheduled visit. STI results may then be available at the time of the physician
48
49 consultation and in the case of a detected STI also immediately treated, limiting the risk of further
50
51 transmission.
52
53

54
55 The objectives of this study were to compare the results of the molecular detection of several STIs
56
57 using the Colli-Pee™ device versus a sample obtained in the clinic, the use and acceptability of the
58
59 Colli-Pee™ device and its convenience for shipment by regular mail. To assess these objectives, a
60

1
2
3 nested sub-study was performed among MSM who participated in a Belgian PrEP demonstration
4 cohort. [14]
5
6
7
8
9

10 11 12 **METHODS:** 13 14

15
16 The evaluation was undertaken as a sub-study of Be-PrEP-ared, a PrEP demonstration study among
17 MSM at high risk for HIV in Belgium.
18
19

20 21 22 **The main study** 23 24

25 The Be-PrEP-ared project (EudraCTn^o: 5015-00005437) was a phase 3, single-site, open-label
26 prospective cohort study where 200 MSM at high risk of acquiring HIV were asked to participate in
27 the project and to take PrEP daily or event-driven. Detailed study methods are described
28 elsewhere.[14] Participants were tested for *Neisseria gonorrhoeae* (NG), *Chlamydia trachomatis* (CT),
29 *Mycoplasma genitalium* (MG) and *Trichomonas vaginalis* (TV) at baseline and every three months.
30 Detection of these STIs was performed at the three biological sites: urethra, anorectum and pharynx.
31 During each study visit, participants collected urine in two urine containers at the clinic as per the
32 following instructions: urinate in the first container up to the marked line at approximately 20 mL,
33 afterwards complete the second cup with no restrictions. Urine in the first container (hereafter the
34 clinic-based sample) was weighed and thereafter stored refrigerated until analysis that took place
35 within 48h. Urine in the second container was used to detect proteinuria.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 55 56 **Laboratory procedures** 57 58

59 In the first instance, CT/NG detection was performed using the Abbott Real Time (RT) CT/NG assay
60 (DNA extraction and sample preparation using Abbott m2000sp and the Abbott m2000rt system for

1
2
3 amplification and detection of CT/NG (Abbott Molecular Inc. Des Plaines, Illinois, USA)) according to
4 manufacturer's instructions. The remainder of the urine and DNA extracts were stored at -80 °C. In
5
6 the case of positivity, the same DNA extracts were tested by in-house real time-PCR (RT-PCR) assays
7
8 for CT and/or NG, both based on previously published primer sets.[15,16]. A sample was considered
9
10 positive when positive in both the Abbott and the in-house RT-PCR. An initial positive Abbott assay
11
12 result followed by a negative confirmatory NAAT result was defined as 'not confirmed'. Inhibition of
13
14 the NAAT according to the Abbott assay was defined as 'inhibition'.
15
16
17

18
19 The same DNA extracts were used for further testing. MG was detected and reported using an
20
21 accredited in-house RT-PCR that targets the pdhD-gene [17] and in addition the DiaMGTV multiplex
22
23 kit (Diagenode diagnostics, Seraing, Belgium) that detects MG and TV simultaneously was used for TV
24
25 detection. The results for MG of the DiaMGTV multiplex kit were not used for reporting purposes and
26
27 are only provided for information only. No further confirmation of TV took place.
28
29
30

31 **The Colli-Pee™ sub-study**

32
33
34 At the baseline visit of the Be-PrEP-ared study, participants were asked consent to participate in this
35
36 sub-study. After signing the informed consent form, they received a Colli-Pee™ device and a prepaid
37
38 envelope. They were instructed to collect first-void urine the next day at home using the Colli-Pee™
39
40 device (the home-based sample), to document the date and time of collection and to send the
41
42 collector tube filled with urine back to the laboratory by regular post, using the prepaid envelope.
43
44
45 Upon receipt in the laboratory, the urine was weighed, stored refrigerated (2-8°C) and CT, NG, MG,
46
47 TV was detected using the same NAATs within 48 hours. The urine and DNA extracts' remnants were
48
49 stored at -80°C. The quantity of human cells was measured at baseline using a human Endogenous
50
51 Retrovirus-3 (ERV-3) quantitative PCR on the paired clinic- and home-based samples.[18]
52
53
54

55
56 The lab technicians were blinded for the results obtained for the clinic-based sample. In addition, the
57
58 result of the home-based sample was not disclosed to the physician or participant.
59
60

1
2
3 During the next visit, which took place within 14 days after baseline, participants were asked to
4 complete a small survey (five questions only) on the user-friendliness and willingness to use the Colli-
5 Pee™ device (acceptability). Two questions documenting their opinion (likes-dislikes) of the Colli-
6 Pee™ device (acceptability). Two questions documenting their opinion (likes-dislikes) of the Colli-
7 Pee™ device (acceptability). Two questions documenting their opinion (likes-dislikes) of the Colli-
8 Pee™ device (acceptability). Two questions documenting their opinion (likes-dislikes) of the Colli-
9 Pee™ device (acceptability). Two questions documenting their opinion (likes-dislikes) of the Colli-
10 Pee™ device were open-ended.

11
12 At follow-up month 6 and month 18 of the study, Colli-Pee™ devices were again distributed to those
13 who agreed to participate and the survey was repeated at month 18 (results unreported).
14

15
16 The main study was approved by the Institutional Review Board of the Institute of Tropical Medicine
17 and the Ethics Committee of the Antwerp University Hospital. In addition, a separate approval for this
18 sub-study was obtained by the Institutional Review Board of the Institute of Tropical Medicine
19 (Ref:1027/15) and this sub-study is also registered in the clinicaltrials.gov database (NCT02552914).
20
21
22
23
24
25
26
27

28 **Patient and Public Involvement**

29
30 Patients were not involved in the Colli-Pee™ substudy. Patients were not invited to comment on the
31 study design and were not consulted to develop patient relevant outcomes or interpret the results.
32
33 Patients were not invited to contribute to the writing or editing of this document for readability or
34 accuracy.
35
36
37
38
39
40

41 **Statistical analysis**

42
43 The agreement of the results of the molecular assays using each of the two sampling methods was
44 assessed by the use of Cohen's kappa statistic and percent agreement. Samples that were not
45 confirmed were coded as negative samples for the calculation of the agreement. The agreement of
46 volume of urine collected and the agreement of concentration of human DNA in both sampling
47 methods was assessed by using a t-test. A p-value of <0.05 was considered statistically significant.
48
49
50
51
52
53
54
55
56 Both analyses were performed using STATA version 15.0 (StataCorp LP, College Station, TX, USA).
57
58
59
60

A descriptive analysis was made of the results of the self-administered questionnaire on the acceptability and user-friendliness of the Colli-Pee™ device.

RESULTS

Demographics

The main study took place at the Institute of Tropical Medicine, Antwerp, Belgium from Sep 2015 until May 2018. Of the 219 participants who were screened for eligibility into the main study, six participants did not consent to the Colli-Pee™ sub-study. All participants who consented to the sub-study were MSM and three identified themselves as transwomen.[19] The mean age of the participants was 38.5 years (Interquartile Range 32-44). A total of 473 home-based samples from 213 participants were received. Two home-based samples could not be linked to the corresponding clinic-based sample and were therefore excluded, bringing the total number to 471. As shown in Table 1, the number of home-based samples received at the laboratory declined over time.

Kind Of Visit	Clinic based	Home Based (% home-based samples received)
Screening	218	187 (85.8%)
Month 6	191	152 (79.6%)
Month 18	179	132 (73.7%)

Table 1: Number of clinic and home-based samples received during the study

Although the participants were instructed to report the urine collection date and hour on the collection device, only 72.8% (343/471) were labelled with collection date. Most of the home-based samples (79.6%) were taken within two days after the clinic-based sample and 3.8% were taken after 20 days (13/343) (median one day; min-max: 0-70 days). The median time between the collection of the home-based sample and its reception at the laboratory after postal return was five days (min-max:

0-27 days), 72.9% arrived at the laboratory within those five days, an additional 25.7% within 10 days and five samples were received after 10 days (11, 13, 15, 17 and 27 days respectively).

Comparison of weight and concentration of human material between both sampling methods.

A total of 455 home-based and 423 clinic-based samples were weighed. The mean net weight of the home-based sample was $19.68\text{g} \pm 2.14\text{g}$ (95%CI: 19.5g-19.9g and min-max: 6.81g-39.47g) vs $22.87\text{g} \pm 13.64\text{g}$ (95%CI: 21.6g-24.2g and min-max: 2.88g - 86.23g) for the clinic-based sample ($p < 0.001$).

The quantity of human cells was analysed at baseline only ($n=187$). In a total of five home-based and one clinic-based sample ERV could not be detected and these samples were considered as lacking human material. After removal of the paired samples lacking ERV or containing inhibitors, 182 observations could be paired. The mean quantity of the clinic-based sample was 11.3×10^3 cells/PCR (95%CI: 7.4 - 15.2×10^3) and for the home-based sample 14.2×10^3 cells/PCR (95% CI: 6.8- 21.5×10^3) ($p > 0.05$).

STI results and agreement

Of the 471 home-based samples with a matching visit, six home-based and one clinic-based sample gave inhibition and were excluded from the analysis ($n=464$). The results are shown in Table 2.

STI	Home-based urine result	Clinic-based urine results		
		Negative	Positive	Total
<i>Chlamydia</i>	Negative	454*	1	455
<i>trachomatis</i>	Positive	3	6	9

STI	Home-based urine result	Clinic-based urine results		
		Negative	Positive	Total
<i>(non-LGV)</i>	Total	457	7	464
<i>Neisseria gonorrhoeae</i>	Negative	455	0	455
	Positive	2	7	9
	Total	457	7	464
<i>Mycoplasma genitalium</i>	Negative	431	2	433
	Positive	6	25	31
	Total	437	27	464
<i>Trichomonas vaginalis</i>	Negative	464	0	464
	Positive	0	0	0
	Total	464	0	464

Table 2: STI results of the home-based and clinic-based urine samples

* Two result were not-confirmed in the clinic-based sample

Trichomonas vaginalis was not detected. Percent agreement (Cohen's kappa coefficient) for CT/NG/MG is 99.1% (0.75); 99.6% (0.87) and 98.3% (0.85), respectively, which indicates substantial agreement for *Chlamydia trachomatis* and almost perfect agreement for the other two STIs.

Tables 3 and 4 show the discordant results. For some of the home-based samples the date of collection was unknown so the time between the clinic visit and time of reception at the laboratory is depicted here. A delta-cycle (DC) value of the Abbott assay of less than two indicates a low positive infection.

STI	DC value	Ct value in- house RT-PCR for CT, NG or MG*	Ct-value S- DiagMGTV RT-PCR (for information only)	Days between collection	Days of transport
CT	1.49	33.19	NA	0	2

MG	NA	32.20	Neg	3	4
MG	NA	32.04	37.44	0	8

Table 3: STI infections that were not detected in home-based urine samples

*: a different in-house RT-PCR assay was used for CT, NG or MG

DC = delta cycle; Ct = Cycle threshold; NA = not applicable; Max = days between clinic visit and reception of the home-based sample at the laboratory

STI	DC value	Ct value in-house RT-PCR for CT, NG or MG*	Ct-value S-DiagMGTV RT-PCR (for information only)	Days between collection	Days of transport
CT	3.99	34.26	NA	1	2
CT	2.68	35.31	NA	1	6
CT	0.27	36.06	NA	6	4
NG	2.93	37.58	NA	8	4
NG	10.08	25.26	NA	2	6
MG	NA	31.28	Neg	Max 6	Max 6
MG	NA	31.96	40.51	1	2
MG	NA	28.66	34.67	Max 3	Max 3
MG	NA	34.58	38.50	9	4
MG	NA	34.23	Neg	1	5
MG	NA	32.04	38.14	Max 3	Max 3

Table 4: STI infections that were additionally detected in home-based urine samples

*: a different in-house RT-PCR assay was used for CT, NG or MG

DC = delta cycle; Ct = Cycle threshold; NA = not applicable; Max = days between clinic visit and reception of the home-based sample at the laboratory

Acceptability and user-friendliness of the Colli-Pee™ device

A total of 164 participants provided feedback regarding the use of the Colli-Pee™ device at baseline.

On a scale of one to five, 87.8% found that the Colli-Pee™ device was easy to very easy to use.

Instructions on how to send the Colli-Pee™ device were found to be easy by 90.2% of the participants.

Four participants found the Colli-Pee™ difficult to use (2.4%) and four other participants found it difficult to follow the instructions (2.4%). Likes from participants were: the ease of use (54.9%), no interruption of the urine flow (15.9%), hygienic (11.6%) and privacy of the home-based sample collection (11.0%); the dislikes were: nothing (47.0%), not being recyclable (14.6%), not hygienic (10.4%) and being too large (6.1%).

To the question of whether they would order an online STI test, 89.0% answered positively (146/164) and 91.1% (133/146) of those individuals would use the Colli-Pee™ device in that case. Six participants (4.1%) would not want to use the Colli-Pee™ device when ordering an online STI test. Participants were also asked how much they would pay for an online STI test with self-sampling. Price indications ranged from 0€ (10 participants) to 60€. Most of the participants (89/164) were willing to pay 10-20€.

DISCUSSION

Many studies have reported on male self-collected urine versus urethra clinician-collected sampling for STI screening, but 'real-world' studies, including sending of home-based urine samples for STI detection in men by post, are sparse.[4,5,20,21] In this study, we showed that the Colli-Pee™ collection device is a valuable and reliable method for collecting first-void urine for STI detection in MSM in Belgium, and that the collector can be shipped by regular post. Compared to the clinic-based sample, a total of three STIs (one CT and two MG infections) were not detected in the home-based sample. However, 11 additional infections were found in home-based samples collected with the Colli-

1
2
3 Pee™ device (3 CT, 2 NG and 6 MG infections). This high number of additional STIs could be explained
4
5 by the fact that first-void urine contains more DNA/RNA than mid-stream and, as a consequence,
6
7 should still be used for STI detection.[9] Indeed, we showed that using the Colli-Pee™ device first-void
8
9 urine was collected in a more standardized way compared to the clinic-based samples ($p < 0.001$).
10
11 Also, more human cells were collected in the home-based samples, however statistical significance
12
13 was lacking. The fact that participants could become positive during the time in between sampling
14
15 points is one of our main limitations and cannot be ignored. Preliminary data of the Be-PrEP-ared
16
17 study showed high incidence estimates after twelve months of the main Be-PrEP-ared study for
18
19 urethral CT/NG and MG: 11.5, 5.1 and 6.9 incidence rate per 100 person-years respectively.
20
21
22

23
24 Nevertheless, the most important observation is that only one Chlamydia positive result was missed.
25
26 The DC value of the Abbott assay performed on that clinic-based sample highlighted the low bacterial
27
28 load of that infection; in addition, transportation at room temperature for two days could have
29
30 induced DNA degradation.
31
32

33
34 The World Health Organisation (WHO) underlines the importance of integrating point-of-care assays
35
36 (POCTs) including innovative delivery options such as self-testing. [22] Unfortunately, to our
37
38 knowledge, current commercial POCTs for the most important STIs such as *Chlamydia trachomatis*
39
40 and *Neisseria gonorrhoeae* are still of sub-optimal quality and do not meet the ASSURED criteria that
41
42 were developed by the WHO STI Diagnostics Initiative.[22–25] A solution to the unavailability of
43
44 qualitative POCTs could be internet-accessed STI testing (e-STI testing) which is increasingly available
45
46 as an alternative to clinic testing all over the world.[26] E-STI testing includes postal self-sampling test
47
48 kits that are sent to a certified laboratory and web-based delivery of test results. Swab2Know, an
49
50 online HIV testing project confirmed that e-HIV testing is acceptable and feasible among MSM in
51
52 Belgium. [27] Commercial online self-sampling services for STIs are now emerging over the internet,
53
54 but evaluation of these services is lacking.
55
56
57
58
59
60

1
2
3 The present study is, however, subject to several limitations. Firstly, we only enrolled Be-PrEP-ared
4 participants and the participation level seriously declined during the study. As a result, our number of
5 CT/NG positives is quite low, which precludes firm conclusions. Secondly, as mentioned above, home-
6 based samples were not taken on the same day as clinic-based sampling and participants could have
7 become positive during that window period. We also do not know whether participants had urinated
8 one hour prior to collection. However, recent data show that the time between micturition is not
9 crucial for the detection of Chlamydia in men.[28] Thirdly, we did not monitor the temperature of the
10 transport of home-based samples which could also have an impact on the quality of the samples,
11 however, outside temperature between Oct 2015 and May 2018 varied between -10°C to 33°C with
12 an average of 11°C.
13
14
15
16
17
18
19
20
21
22
23
24
25

26 Fourthly, we cannot exclude specimen contamination, however, participants were instructed how to
27 correctly collect the clinic-based and home-based sample. Finally, reporting bias is also not to be
28 excluded. Not all participants who used a Colli-Pee™ device completed the survey, the additional
29 questions were included at the end of the lengthy main questionnaire of the Be-PrEP-ared study.
30
31
32
33
34
35

36 Besides PrEP users, e-STI testing has the potential to reach those who are most in need and a recent
37 study showed that some higher-risk groups, such as MSM, were more likely to use online services
38 [26,29]. Many studies have shown that home-based sampling is well accepted and, in fact, is the
39 preferred approach in these groups for STIs. Reasons for choosing home-based sampling were shorter
40 waiting times for results, convenience and less embarrassment. [30] Participants views regarding
41 ordering an online STI test in this study were very positive, 89% would like to order such a kit. The
42 Colli-Pee™ device was also found to be easy (90.2%) and although hygiene was one of the likes, it also
43 appeared in the dislikes, probably because the need to detach the collector manually can cause
44 leakage of urine. Participants were also concerned regarding possible ecological consequences,
45 although the plastic material is recyclable and can be incinerated into energy.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 We demonstrated that postal delivery of home-based collected urine does not influence STI detection
4 and can be used among PrEP users. Subsequently, PrEP users will be able to send first-void urine to
5 the laboratory with the Colli-Pee™ device one to two weeks before their routine PrEP follow up visit.
6
7 Results can then be discussed during the physician consultation and followed by treatment and future
8 antimicrobial testing if applicable, decreasing the number of physician visits. Decreasing the number
9 of face-to-face visits will lower the burden on staff workload and healthcare resources. However,
10 future economic evaluations will need to be conducted to prove this statement. E-STI testing could be
11 a promising approach in Belgium to reach patients in hard-to-reach populations and research on this
12 topic should be stimulated. Therefore, future studies to study the acceptability and impact of postal
13 shipment of home-collected material on the performance of STI assays requires additional
14 assessment.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 Figure legend: Fig 1: The Colli-Pee™ device instructions for use.
32

33 34 35 **ACKNOWLEDGEMENTS** 36 37 38

39 We would like to thank all the participants of the Be-PrEP-ared study who participated in this small
40 study. We also would like to thank Be-PrEP-ared study group but especially Maureen Aerts who was
41 crucial in the participation level of this study. Finally we would like to thank Wendy Thys for the data
42 entry.
43
44
45
46
47
48

49 50 **COMPETING INTERESTS STATEMENT** 51 52 53

54 The authors have no competing interests to declare.
55
56
57
58
59
60

FUNDING STATEMENT

This work was supported by Novosanis who provided the Colli-Pee™ devices and partially paid for the analyses performed on the home-based samples. In addition, a grant was obtained from the Flemish Agency for Innovation and Entrepreneurship to conduct the Be-PrEP-ared study.

DATASHARING STATEMENT

The data will be made publicly available except for the use and acceptability data as these will be retained at the Institute of Tropical Medicine (ITM), Antwerp due to ethical and privacy concerns. According to the ITM research data sharing policy, only fully anonymised data can be shared publicly. The data can however be made available after approval of a motivated and written request to the ITM at ITMresearchdataaccess@itg.be. The ITM data access committee will verify if the dataset is suitable for obtaining the study objective and assure that confidentiality and ethical requirements are in place.

CONTRIBUTORSHIP STATEMENT

IDB, TC, and BV designed the study. TR designed the acceptability survey. IDB performed the statistical analysis and wrote the first draft of the manuscript. HS, BDD, VC, SA performed testing. All authors read the final version of the manuscript and provided comments.

REFERENCES

- 1 WHO. Global Health Sector Strategy on Sexually Transmitted Infections 2016-2021. *World Heal Organ* 2016;**1**:63. doi:10.1055/s-2007-970201.
- 2 Lanjouw E, Ouburg S, de Vries H, *et al*. 2015 European guideline on the management of *Chlamydia trachomatis* infections. *Int J STD AIDS* 2016;**27**:333–48.

- 1
2
3 doi:10.1177/0956462415618837
4
5
6 3 Bignell C, Unemo M, Radcliffe K, *et al.* 2012 European guideline on the diagnosis and
7
8 treatment of gonorrhoea in adults. *Int J STD AIDS* 2013;**24**:85–92.
9
10 doi:10.1177/0956462412472837
11
12
13 4 Lunny C, Taylor D, Hoang L, *et al.* Self-Collected versus Clinician-Collected Sampling for
14
15 Chlamydia and Gonorrhoea Screening: A Systemic Review and Meta-Analysis. *PLoS One*
16
17 2015;**10**:e0132776. doi:10.1371/journal.pone.0132776
18
19
20
21 5 McNicol J, Debattista J. Use of the UriSwab collection device for testing of *Chlamydia*
22
23 *trachomatis* and *Neisseria gonorrhoeae* : implications for a postal testing service. *Int J STD*
24
25 *AIDS* 2013;**24**:477–80. doi:10.1177/0956462412472834
26
27
28 6 Vorsters A, Van den Bergh J, Micalessi I, *et al.* Optimization of HPV DNA detection in urine by
29
30 improving collection, storage, and extraction. *Eur J Clin Microbiol Infect Dis* 2014;**33**:2005–14.
31
32 doi:10.1007/s10096-014-2147-2
33
34
35 7 Theodorescu D, Schiffer E, Bauer HW, *et al.* Discovery and validation of urinary biomarkers for
36
37 prostate cancer. *Proteomics Clin Appl* 2008;**2**:556–70. doi:10.1002/prca.200780082
38
39
40 8 Wisniewski CA, White JA, Michel C-EC, *et al.* Optimal method of collection of first-void urine
41
42 for diagnosis of *Chlamydia trachomatis* infection in men. *J Clin Microbiol* 2008;**46**:1466–9.
43
44 doi:10.1128/JCM.02241-07
45
46
47 9 Johnson DJ, Calderaro AC, Roberts KA. Variation in Nuclear DNA Concentrations During
48
49 Urination. *J Forensic Sci* 2007;**52**:110–3. doi:10.1111/j.1556-4029.2006.00329.x
50
51
52
53 10 Traeger MW, Schroeder SE, Wright EJ, *et al.* Effects of Pre-exposure Prophylaxis for the
54
55 Prevention of Human Immunodeficiency Virus Infection on Sexual Risk Behavior in Men Who
56
57 Have Sex With Men: A Systematic Review and Meta-analysis. *Clin Infect Dis* Published Online
58
59 First: 2 March 2018. doi:10.1093/cid/ciy182
60

- 1
2
3 11 Kojima N, Davey DJ, Klausner JD. Pre-exposure prophylaxis for human immunodeficiency
4 virus and sexually transmitted infection acquisition among men who have sex with men. *AIDS*
5
6 Published Online First: 2016. doi:10.1097/QAD.0000000000001185
7
8
9
10
11 12 Salazar NAMEJ. EACS HIV guidelines 8.1. 2016.
12
13
14 13 WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection. *Geneva*
15
16 *World Heal Organ* Published Online First: 2017.[http://www.who.int/hiv/pub/prep/prep-](http://www.who.int/hiv/pub/prep/prep-implementation-tool/en/)
17
18 [implementation-tool/en/](http://www.who.int/hiv/pub/prep/prep-implementation-tool/en/) (accessed 21 Aug 2018).
19
20
21 14 De Baetselier I, Reyniers T, Nöstlinger C, *et al.* Pre-Exposure Prophylaxis (PrEP) as an
22
23 Additional Tool for HIV Prevention Among Men Who Have Sex With Men in Belgium: The Be-
24
25 PrEP-ared Study Protocol. *JMIR Res Protoc* 2017;**6**:e11. doi:10.2196/resprot.6767
26
27
28 15 Chen C-Y, Chi KH, Alexander S, *et al.* A real-time quadriplex PCR assay for the diagnosis of
29
30 rectal lymphogranuloma venereum and non-lymphogranuloma venereum Chlamydia
31
32 trachomatis infections. *Sex Transm Infect* 2008;**84**:273–6. doi:10.1136/sti.2007.029058
33
34
35 16 Hopkins MJ, Ashton LJ, Alloba F, *et al.* Validation of a laboratory-developed real-time PCR
36
37 protocol for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine. *Sex*
38
39 *Transm Infect* 2010;**86**:207–11. doi:10.1136/sti.2009.040634
40
41
42 17 Müller EE, Venter JME, Magooa MP, *et al.* Development of a rotor-gene real-time PCR assay
43
44 for the detection and quantification of Mycoplasma genitalium. *J Microbiol Methods*
45
46 2012;**88**:311–5. doi:10.1016/j.mimet.2011.12.017
47
48
49 18 Yuan CC, Miley W, Waters D. A quantification of human cells using an ERV-3 real time PCR
50
51 assay. *J Virol Methods* 2001;**91**:109–17.
52
53
54
55 19 Reyniers T, Nöstlinger C, Laga M, *et al.* Choosing between daily and event-driven Pre-
56
57 Exposure Prophylaxis: results of a Belgian PrEP demonstration project Conflict of Interest and
58
59 Source of Funding: A grant was obtained from the Flemish Agency for. *JAIDS J Acquir Immune*
60

- 1
2
3 *Defic Syndr Publ Ahead Print* doi:10.1097/QAI.0000000000001791
4
5
6 20 Morr  SA, van Valkengoed IG, de Jong A, *et al*. Mailed, home-obtained urine specimens: a
7
8 reliable screening approach for detecting asymptomatic Chlamydia trachomatis infections. *J*
9
10 *Clin Microbiol* 1999;**37**:976–80.<http://www.ncbi.nlm.nih.gov/pubmed/10074512> (accessed
11
12 21 Aug 2018).
- 13
14
15 21 Fajardo-Bernal L, Aponte-Gonzalez J, Vigil P, *et al*. Home-based versus clinic-based specimen
16
17 collection in the management of Chlamydia trachomatis and Neisseria gonorrhoeae
18
19 infections. *Cochrane Database Syst Rev* 2015;:CD011317.
20
21 doi:10.1002/14651858.CD011317.pub2
22
23
24
25 22 Toskin I, Blondeel K, Peeling RW, *et al*. Advancing point of care diagnostics for the control and
26
27 prevention of STIs: the way forward. *Sex Transm Infect* 2017;**93**:S81–8. doi:10.1136/sextrans-
28
29 2016-053073
30
31
32
33 23 De Baetselier I, Mwambarangwe L, Cuylaerts V, *et al*. Evaluation of an enzymatic Chlamydia
34
35 trachomatis point-of-care rapid assay in Rwanda: the BioChekSwab Rapid Test. *Sex Transm*
36
37 *Infect* Published Online First: 16 October 2015. doi:10.1136/sextrans-2015-052202
38
39
40
41 24 Peeling RW, Holmes KK, Mabey D, *et al*. Rapid tests for sexually transmitted infections (STIs):
42
43 the way forward. *Sex Transm Infect* 2006;**82**:v1–6. doi:10.1136/sti.2006.024265
44
45
46 25 European Centre for Disease Prevention and Control. Novel approaches to testing for sexually
47
48 transmitted infections, including HIV and hepatitis B and C in Europe. Stockholm: 2012.
49
50 doi:10.2900/6481
51
52
53 26 Wilson E, Free C, Morris TP, *et al*. Internet-accessed sexually transmitted infection (e-STI)
54
55 testing and results service: A randomised, single-blind, controlled trial. *PLOS Med*
56
57 2017;**14**:e1002479. doi:10.1371/journal.pmed.1002479
58
59
60 27 Platteau T, Fransen K, Apers L, *et al*. Swab2know: An HIV-Testing Strategy Using Oral Fluid

- 1
2
3 Samples and Online Communication of Test Results for Men Who Have Sex With Men in
4 Belgium. *J Med Internet Res* 2015;**17**:e213. doi:10.2196/jmir.4384
5
6
7
8 28 Mathew T, O'Mahony C, Mallinson H. Shortening the voiding interval for men having
9 chlamydia nucleic acid amplification tests. *Int J STD AIDS* 2009;**20**:752–3.
10
11 doi:10.1258/ijisa.2009.009225
12
13
14
15 29 Barnard S, Free C, Bakolis I, *et al*. Comparing the characteristics of users of an online service
16 for STI self-sampling with clinic service users: a cross-sectional analysis. *Sex Transm Infect*
17
18 2018;:sextrans-2017-053302. doi:10.1136/sextrans-2017-053302
19
20
21
22
23 30 Paudyal P, Llewellyn C, Lau J, *et al*. Obtaining self-samples to diagnose curable sexually
24 transmitted infections: a systematic review of patients' experiences. *PLoS One*
25
26 2015;**10**:e0124310. doi:10.1371/journal.pone.0124310
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Fig 1: The Colli-Pee™ device instructions for use.

268x110mm (95 x 95 DPI)

Section & Topic	No	Item	Reported on page #
TITLE OR ABSTRACT			
	1	Identification as a study of diagnostic accuracy using at least one measure of accuracy (such as sensitivity, specificity, predictive values, or AUC)	2 (agreement was used as this is not a diagnostic study)
ABSTRACT			
	2	Structured summary of study design, methods, results, and conclusions (for specific guidance, see STARD for Abstracts)	2
INTRODUCTION			
	3	Scientific and clinical background, including the intended use and clinical role of the index test	3-4
	4	Study objectives and hypotheses	4
METHODS			
<i>Study design</i>	5	Whether data collection was planned before the index test and reference standard were performed (prospective study) or after (retrospective study)	5
<i>Participants</i>	6	Eligibility criteria	5
	7	On what basis potentially eligible participants were identified (such as symptoms, results from previous tests, inclusion in registry)	5-6
	8	Where and when potentially eligible participants were identified (setting, location and dates)	5
	9	Whether participants formed a consecutive, random or convenience series	5-6
<i>Test methods</i>	10a	Index test, in sufficient detail to allow replication	Not applicable same assay was used on both samples (but different kind of sample)
	10b	Reference standard, in sufficient detail to allow replication	Not applicable same assay was used on both samples (but different kind of sample)
	11	Rationale for choosing the reference standard (if alternatives exist)	Not applicable same assay was used on both samples (but different kind of sample)
	12a	Definition of and rationale for test positivity cut-offs or result categories of the index test, distinguishing pre-specified from exploratory	5-6
	12b	Definition of and rationale for test positivity cut-offs or result categories of the reference standard, distinguishing pre-specified from exploratory	5-6
	13a	Whether clinical information and reference standard results were available to the performers/readers of the index test	6
	13b	Whether clinical information and index test results were available to the assessors of the reference standard	6
<i>Analysis</i>	14	Methods for estimating or comparing measures of diagnostic accuracy	7
	15	How indeterminate index test or reference standard results were handled	6
	16	How missing data on the index test and reference standard were handled	Not applicable
	17	Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from exploratory	Not applicable
	18	Intended sample size and how it was determined	Not applicable
RESULTS			
<i>Participants</i>	19	Flow of participants, using a diagram	We did not include of flow of participants, however this has been discussed in the text p7-8

1		20	Baseline demographic and clinical characteristics of participants	7-8
2		21a	Distribution of severity of disease in those with the target condition	Not applicable
3		21b	Distribution of alternative diagnoses in those without the target condition	Not applicable
4		22	Time interval and any clinical interventions between index test and reference standard	8
5	<i>Test results</i>	23	Cross tabulation of the index test results (or their distribution) by the results of the reference standard	8
6		24	Estimates of diagnostic accuracy and their precision (such as 95% confidence intervals)	Cohen's kappa agreement was used p9
7		25	Any adverse events from performing the index test or the reference standard	Not applicable
8				
9				
10		25	Any adverse events from performing the index test or the reference standard	Not applicable
11	DISCUSSION			
12		26	Study limitations, including sources of potential bias, statistical uncertainty, and generalisability	13
13		27	Implications for practice, including the intended use and clinical role of the index test	13-14
14				
15	OTHER INFORMATION			
16				
17		28	Registration number and name of registry	6
18		29	Where the full study protocol can be accessed	Will be added as appendix
19		30	Sources of funding and other support; role of funders	15
20				
21				
22				
23				
24				
25				
26				
27				
28				
29				
30				
31				
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

STARD 2015

AIM

STARD stands for “Standards for Reporting Diagnostic accuracy studies”. This list of items was developed to contribute to the completeness and transparency of reporting of diagnostic accuracy studies. Authors can use the list to write informative study reports. Editors and peer-reviewers can use it to evaluate whether the information has been included in manuscripts submitted for publication.

EXPLANATION

A **diagnostic accuracy study** evaluates the ability of one or more medical tests to correctly classify study participants as having a **target condition**. This can be a disease, a disease stage, response or benefit from therapy, or an event or condition in the future. A medical test can be an imaging procedure, a laboratory test, elements from history and physical examination, a combination of these, or any other method for collecting information about the current health status of a patient.

The test whose accuracy is evaluated is called **index test**. A study can evaluate the accuracy of one or more index tests. Evaluating the ability of a medical test to correctly classify patients is typically done by comparing the distribution of the index test results with those of the **reference standard**. The reference standard is the best available method for establishing the presence or absence of the target condition. An accuracy study can rely on one or more reference standards.

If test results are categorized as either positive or negative, the cross tabulation of the index test results against those of the reference standard can be used to estimate the **sensitivity** of the index test (the proportion of participants *with* the target condition who have a positive index test), and its **specificity** (the proportion *without* the target condition who have a negative index test). From this cross tabulation (sometimes referred to as the contingency or “2x2” table), several other accuracy statistics can be estimated, such as the positive and negative **predictive values** of the test. Confidence intervals around estimates of accuracy can then be calculated to quantify the statistical **precision** of the measurements.

If the index test results can take more than two values, categorization of test results as positive or negative requires a **test positivity cut-off**. When multiple such cut-offs can be defined, authors can report a receiver operating characteristic (ROC) curve which graphically represents the combination of sensitivity and specificity for each possible test positivity cut-off. The **area under the ROC curve** informs in a single numerical value about the overall diagnostic accuracy of the index test.

The **intended use** of a medical test can be diagnosis, screening, staging, monitoring, surveillance, prediction or prognosis. The **clinical role** of a test explains its position relative to existing tests in the clinical pathway. A replacement test, for example, replaces an existing test. A triage test is used before an existing test; an add-on test is used after an existing test.

Besides diagnostic accuracy, several other outcomes and statistics may be relevant in the evaluation of medical tests. Medical tests can also be used to classify patients for purposes other than diagnosis, such as staging or prognosis. The STARD list was not explicitly developed for these other outcomes, statistics, and study types, although most STARD items would still apply.

DEVELOPMENT

This STARD list was released in 2015. The 30 items were identified by an international expert group of methodologists, researchers, and editors. The guiding principle in the development of STARD was to select items that, when reported, would help readers to judge the potential for bias in the study, to appraise the applicability of the study findings and the validity of conclusions and recommendations. The list represents an update of the first version, which was published in 2003.

More information can be found on <http://www.equator-network.org/reporting-guidelines/stard>.



BMJ Open

EVALUATION OF THE "COLLI-PEETM", A FIRST-VOID URINE COLLECTION DEVICE FOR SELF-SAMPLING AT HOME FOR THE DETECTION OF SEXUALLY TRANSMITTED INFECTIONS, VERSUS A ROUTINE CLINIC BASED URINE COLLECTION IN A ONE-TO-ONE COMPARISON STUDY DESIGN: EFFICACY AND ACCEPTABILITY AMONG MSM IN BELGIUM

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028145.R2
Article Type:	Research
Date Submitted by the Author:	28-Feb-2019
Complete List of Authors:	De Baetselier, Irith; Institute of Tropical Medicine, Department of Clinical Sciences Smet, Hilde; Institute of Tropical Medicine, Department of Clinical Sciences Abdellati, Said; Institute of Tropical Medicine, Department of Clinical Sciences De Deken, Bénédicte; Institute of Tropical Medicine, Department of Clinical Sciences Cuylaerts, Vicky; Institute of Tropical Medicine, Department of Clinical Sciences Reyniers, Thijs; Institute of Tropical Medicine, Department of Public Health Vuylsteke, Bea; Institute of Tropical Medicine, Public Health Crucitti, Tania; Institute of Tropical Medicine, Department of Clinical Sciences
Primary Subject Heading:	Sexual health
Secondary Subject Heading:	Diagnostics
Keywords:	neisseria gonorrhoeae, chlamydia trachomatis, screening, urine, pre-exposure prophylaxis, MSM

SCHOLARONE™
Manuscripts

1
2
3
4
5 **EVALUATION OF THE “COLLI-PEE™”, A FIRST-VOID URINE**
6
7
8
9
10 **COLLECTION DEVICE FOR SELF-SAMPLING AT HOME**
11
12
13
14 **FOR THE DETECTION OF SEXUALLY TRANSMITTED**
15
16
17
18 **INFECTIONS, VERSUS A ROUTINE CLINIC BASED URINE**
19
20
21
22
23 **COLLECTION IN A ONE-TO-ONE COMPARISON STUDY**
24
25
26
27
28 **DESIGN: EFFICACY AND ACCEPTABILITY AMONG MSM IN**
29
30
31
32 **BELGIUM**

33
34
35
36
37
38
39 Authors: De Baetselier Irith¹, Smet Hilde¹, Abdellati Saïd¹, De Deken Bénédicte¹, Cuylaerts Vicky¹,
40
41 Reyniers Thijs², Vuylsteke Bea², Crucitti Tania¹

42
43
44
45 ¹Institute of Tropical Medicine, Department of Clinical Sciences, HIV/STI Reference Laboratory,
46
47 Antwerp, Belgium

48
49
50 ²Institute of Tropical Medicine, Department of Public Health, HIV Sexual Unit, Antwerp, Belgium

51
52
53 Corresponding Author Details:

54
55 Irith De Baetselier MSc.

56
57 Institute of Tropical Medicine

58
59 Nationalestraat 155
60

1
2
3 2000 Antwerp
4

5 Belgium
6

7 Email: idebaetselier@itg.be
8

9
10 Telephone: +3232475444
11

12 Wordcount excluding title page, abstract, references, figures and tables: 3332
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ABSTRACT:

Objectives: Pre-exposure prophylaxis (PrEP) users are screened bi-annual for Sexually Transmitted Infections (STIs). A novel device, called the Colli-Pee™, collects first-void urine in a standardized way and the collector tube can be easily delivered by regular post to a certified laboratory. The aim of the study was a one-to-one comparison between the STI test results obtained with the urine collected in the clinic, versus urine collected at home in a real-life setting by Men who have Sex with Men (MSM) in Belgium. The user-friendliness and acceptability of the Colli-Pee™ device by the users was also evaluated.

Design: A single-site nested sub-study in a prospective PrEP demonstration project (Be-PrEP-ared) among MSM in Belgium.

Participants: A total of 473 home-based samples from 213 MSM were received with a mean age of 38.5 years.

Interventions: Participants were requested to collect a urine sample at home using the Colli-Pee™ device and to send it to the laboratory via regular mail.

Primary and secondary outcome measures: The presence of *Chlamydia trachomatis* (CT), *Neisseria gonorrhoeae* (NG), *Mycoplasma genitalium* (MG) and *Trichomonas vaginalis* (TV) was determined using molecular amplification assays. Agreement between test results of samples collected at the clinic and collected at home were evaluated using Cohen's kappa statistic. Results: *Trichomonas vaginalis* was not detected. A very good to almost perfect agreement was found for CT, NG and MG of $\kappa=0.75$; 0.87 and 0.85, respectively. Using the Colli-Pee™ device only one low positive CT and two MG infections were missed, however, three additional CT, two NG and six MG infections were detected.

1
2
3 Conclusions: The Colli-Pee™ device is a feasible and convenient way to collect urine at home for STI
4 testing. This may be particularly relevant for populations that need frequent STI testing, such as PrEP
5 users, and patients who prefer home-sampling.
6
7
8
9

10 Trial registration: Clinicaltrials.gov database: NCT02552914
11
12
13

14 ARTICLE SUMMARY

17 Strengths and limitations of this study

- 20 • The study was designed as such to provide real-world experience concerning home-based
21 sampling for STI detection including shipment by post among PrEP users.
22
- 23 • Home-based and clinic-based samples were processed and analyzed using the same
24 procedures and laboratory staff was blinded for the results of the matching sample.
25
- 26 • The study was performed among MSM PrEP users who have a high prevalence of STIs.
27
- 28 • Our main limitation is that home-based samples were not taken on the same day as clinic-
29 based sampling and participants could have become positive during that window period.
30
- 31 • Another limitation of the study is that the temperature during transportation of home-based
32 samples to the clinic was not monitored.
33
34
35
36
37
38
39
40
41

42 INTRODUCTION:

43
44
45
46 According to the World Health Organisation's Global Health Sector Strategy on Sexually Transmitted
47 Infections (STIs) 2016-2021, early diagnosis and linkage to treatment are one of the key elements for
48 preventing further transmission of STIs.[1] Currently, first-void urine is still favoured as the sample of
49 choice for the detection of *Chlamydia trachomatis* (CT) and *Neisseria gonorrhoeae* (NG) in men, using
50 nucleic acid amplification tests (NAATs).[2–4] In general, a regular urine container is used to collect
51 the first-void urine sample, but the collected volume of urine is not standardized. Furthermore, this
52 type of container is less convenient for postal delivery to the laboratory. Another sponged-based
53
54
55
56
57
58
59
60

1
2
3 device (UriSWAB, Copan Diagnostics, Brescia, Italy) has been suggested as an alternative for postal
4 delivery of urine. However, this device only holds 2 mL of urine and does not guarantee that only first-
5 void urine is collected.[4,5] The CE-IVD labelled Colli-Pee™ device (Novosanis, Belgium), provides a
6 clean and standardized solution to the above-mentioned issues as it efficiently captures first-void
7 urine (20 mL) without interruption of the urine flow and allows the samples to be sent by post. (Fig 1)
8 The Colli-Pee™ device is currently used for the detection of Human Papilloma Virus (HPV) and several
9 urological cancers for which collection of first-void urine is essential.[6,7] In the field of STIs, a
10 standardized first-void urine study reported that the organism load of *C. trachomatis* is maximal in the
11 first 4-5 mL and that the performance of diagnostic tests improved when using only first-void
12 urine.[8,9]

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29 Although pre-exposure prophylaxis (PrEP) is becoming crucial in HIV prevention, recent reviews of
30 real-world PrEP demonstration studies showed that PrEP is associated with increased diagnoses of
31 STIs in Men who have Sex with Men (MSM).[10,11] Consequently, current guidelines recommend a
32 bi-annual screening of STIs in PrEP users because of their high risk behaviour.[12,13]

33
34
35
36
37
38
39 In order to facilitate the patient flow during follow-up visits by PrEP users, and prompt treatment of
40 STIs, home-based collection of first-void urine could be sent to the laboratory by regular mail for STI
41 detection before the scheduled visit. STI results may then be available at the time of the physician
42 consultation and in the case of a detected STI also immediately treated, limiting the risk of further
43 transmission.

44
45
46
47
48
49
50 The objectives of this study were to compare the results of the molecular detection of several STIs
51 using the Colli-Pee™ device versus a sample obtained in the clinic, the use and acceptability of the
52 Colli-Pee™ device and its convenience for shipment by regular mail. To assess these objectives, a
53 nested sub-study was performed among MSM who participated in a Belgian PrEP demonstration
54 cohort. [14]

METHODS:

The evaluation was undertaken as a sub-study of Be-PrEP-ared, a PrEP demonstration study among MSM at high risk for HIV in Belgium.

The main study

The Be-PrEP-ared project (EudraCTn^o: 5015-00005437) was a phase 3, single-site, open-label prospective cohort study where 200 MSM at high risk of acquiring HIV were asked to participate in the project and to take PrEP daily or event-driven. Detailed study methods are described elsewhere.[14] Participants were tested for *Neisseria gonorrhoeae* (NG), *Chlamydia trachomatis* (CT), *Mycoplasma genitalium* (MG) and *Trichomonas vaginalis* (TV) at baseline and every three months. Detection of these STIs was performed at the three biological sites: urethra, anorectum and pharynx. During each study visit, participants collected urine in two urine containers at the clinic as per the following instructions: urinate in the first container up to the marked line at approximately 20 mL, afterwards complete the second cup with no restrictions. Urine in the first container (hereafter the clinic-based sample) was weighed and thereafter stored refrigerated until analysis that took place within 48h. Urine in the second container was used to detect proteinuria.

Laboratory procedures

In the first instance, CT/NG detection was performed using the Abbott Real Time (RT) CT/NG assay (DNA extraction and sample preparation using Abbott m2000sp and the Abbott m2000rt system for amplification and detection of CT/NG (Abbott Molecular Inc. Des Plaines, Illinois, USA)) according to manufacturer's instructions. The remainder of the urine and DNA extracts were stored at -80 °C. In

1
2
3 the case of positivity, the same DNA extracts were tested by in-house real time-PCR (RT-PCR) assays
4 for CT and/or NG, both based on previously published primer sets.[15,16]. A sample was considered
5
6 for CT and/or NG, both based on previously published primer sets.[15,16]. A sample was considered
7
8 positive when positive in both the Abbott and the in-house RT-PCR. An initial positive Abbott assay
9
10 result followed by a negative confirmatory NAAT result was defined as 'not confirmed'. Inhibition of
11
12 the NAAT according to the Abbott assay was defined as 'inhibition'.
13
14

15 The same DNA extracts were used for further testing. MG was detected and reported using an
16
17 accredited in-house RT-PCR that targets the pdhD-gene [17] and in addition the DiaMGTV multiplex
18
19 kit (Diagenode diagnostics, Seraing, Belgium) that detects MG and TV simultaneously was used for TV
20
21 detection. The results for MG of the DiaMGTV multiplex kit were not used for reporting purposes and
22
23 are only provided for information only. No further confirmation of TV took place.
24
25
26

27 **The Colli-Pee™ sub-study**

28
29
30 At the baseline visit of the Be-PrEP-ared study, participants were asked consent to participate in this
31
32 sub-study. After signing the informed consent form, they received a Colli-Pee™ device and a prepaid
33
34 envelope. They were instructed to collect first-void urine the next day at home using the Colli-Pee™
35
36 device (the home-based sample), to document the date and time of collection and to send the
37
38 collector tube filled with urine back to the laboratory by regular post, using the prepaid envelope.
39
40 Upon receipt in the laboratory, the urine was weighed, stored refrigerated (2-8°C) and CT, NG, MG,
41
42 TV was detected using the same NAATs within 48 hours. The urine and DNA extracts' remnants were
43
44 stored at -80°C. The quantity of human cells was measured at baseline using a human Endogenous
45
46 Retrovirus-3 (ERV-3) quantitative PCR on the paired clinic- and home-based samples.[18]
47
48
49

50
51 The lab technicians were blinded for the results obtained for the clinic-based sample. In addition, the
52
53 result of the home-based sample was not disclosed to the physician or participant.
54
55

56 During the next visit, which took place within 14 days after baseline, participants were asked to
57
58 complete a small survey (five questions only) on the user-friendliness and willingness to use the Colli-
59
60

1
2
3 Pee™ device (acceptability). Two questions documenting their opinion (likes-dislikes) of the Colli-
4
5 Pee™ device were open-ended.
6
7

8 At follow-up month 6 and month 18 of the study, Colli-Pee™ devices were again distributed to those
9
10 who agreed to participate and the survey was repeated at month 18 (results unreported).
11
12

13 The main study was approved by the Institutional Review Board of the Institute of Tropical Medicine
14
15 and the Ethics Committee of the Antwerp University Hospital. In addition, a separate approval for this
16
17 sub-study was obtained by the Institutional Review Board of the Institute of Tropical Medicine
18
19 (Ref:1027/15) and this sub-study is also registered in the clinicaltrials.gov database (NCT02552914).
20
21
22

23 **Patient and Public Involvement**

24
25 Patients were not involved in the Colli-Pee™ substudy. Patients were not invited to comment on the
26
27 study design and were not consulted to develop patient relevant outcomes or interpret the results.
28
29 Patients were not invited to contribute to the writing or editing of this document for readability or
30
31 accuracy.
32
33
34
35

36 **Statistical analysis**

37
38 The agreement of the results of the molecular assays using each of the two sampling methods was
39
40 assessed by the use of Cohen's kappa statistic and percent agreement. Samples that were not
41
42 confirmed were coded as negative samples for the calculation of the agreement. The agreement of
43
44 volume of urine collected and the agreement of concentration of human DNA in both sampling
45
46 methods was assessed by using a t-test. A p-value of <0.05 was considered statistically significant.
47
48 Both analyses were performed using STATA version 15.0 (StataCorp LP, College Station, TX, USA).
49
50
51
52

53
54 A descriptive analysis was made of the results of the self-administered questionnaire on the
55
56 acceptability and user-friendliness of the Colli-Pee™ device.
57
58
59
60

RESULTS

Demographics

The main study took place at the Institute of Tropical Medicine, Antwerp, Belgium from Sep 2015 until May 2018. Of the 219 participants who were screened for eligibility into the main study, six participants did not consent to the Colli-Pee™ sub-study. All participants who consented to the sub-study were MSM and three identified themselves as transwomen.[19] The mean age of the participants was 38.5 years (Interquartile Range 32-44). A total of 473 home-based samples from 213 participants were received. Two home-based samples could not be linked to the corresponding clinic-based sample and were therefore excluded, bringing the total number to 471. As shown in Table 1, the number of home-based samples received at the laboratory declined over time.

Kind Of Visit	Clinic based	Home Based (% home-based samples received)
Screening	218	187 (85.8%)
Month 6	191	152 (79.6%)
Month 18	179	132 (73.7%)

Table 1: Number of clinic and home-based samples received during the study

Although the participants were instructed to report the urine collection date and hour on the collection device, only 72.8% (343/471) were labelled with collection date. Most of the home-based samples (79.6%) were taken within two days after the clinic-based sample and 3.8% were taken after 20 days (13/343) (median one day; min-max: 0-70 days). The median time between the collection of the home-based sample and its reception at the laboratory after postal return was five days (min-max: 0-27 days), 72.9% arrived at the laboratory within those five days, an additional 25.7% within 10 days and five samples were received after 10 days (11, 13, 15, 17 and 27 days respectively).

Comparison of weight and concentration of human material between both sampling methods.

A total of 455 home-based and 423 clinic-based samples were weighed. The mean net weight of the home-based sample was $19.68\text{g} \pm 2.14\text{g}$ (95%CI: 19.5g-19.9g and min-max: 6.81g-39.47g) vs $22.87\text{g} \pm 13.64\text{g}$ (95%CI: 21.6g-24.2g and min-max: 2.88g - 86.23g) for the clinic-based sample ($p < 0.001$).

The quantity of human cells was analysed at baseline only ($n=187$). In a total of five home-based and one clinic-based sample ERV could not be detected and these samples were considered as lacking human material. After removal of the paired samples lacking ERV or containing inhibitors, 182 observations could be paired. The mean quantity of the clinic-based sample was 11.3×10^3 cells/PCR (95%CI: 7.4 - 15.2×10^3) and for the home-based sample 14.2×10^3 cells/PCR (95% CI: 6.8- 21.5×10^3) ($p > 0.05$).

STI results and agreement

Of the 471 home-based samples with a matching visit, six home-based and one clinic-based sample gave inhibition and were excluded from the analysis ($n=464$). The results are shown in Table 2.

STI	Home-based urine result	Clinic-based urine results		
		Negative	Positive	Total
<i>Chlamydia</i>	Negative	454*	1	455
<i>trachomatis</i>	Positive	3	6	9
(non-LGV)	Total	457	7	464
<i>Neisseria</i>	Negative	455	0	455

STI	Home-based urine result	Clinic-based urine results		
		Negative	Positive	Total
<i>gonorrhoeae</i>	Positive	2	7	9
	Total	457	7	464
<i>Mycoplasma genitalium</i>	Negative	431	2	433
	Positive	6	25	31
	Total	437	27	464
<i>Trichomonas vaginalis</i>	Negative	464	0	464
	Positive	0	0	0
	Total	464	0	464

Table 2: STI results of the home-based and clinic-based urine samples

* Two result were not-confirmed in the clinic-based sample

Trichomonas vaginalis was not detected. Percent agreement (Cohen's kappa coefficient) for CT/NG/MG is 99.1% (0.75); 99.6% (0.87) and 98.3% (0.85), respectively, which indicates substantial agreement for *Chlamydia trachomatis* and almost perfect agreement for the other two STIs.

Tables 3 and 4 show the discordant results. For some of the home-based samples the date of collection was unknown so the time between the clinic visit and time of reception at the laboratory is depicted here. A delta-cycle (DC) value of the Abbott assay of less than two indicates a low positive infection.

STI	DC value	Ct value in-house RT-PCR for CT, NG or MG*	Ct-value S-DiagMGTV RT-PCR (for information only)	Days between collection	Days of transport
CT	1.49	33.19	NA	0	2
MG	NA	32.20	Neg	3	4
MG	NA	32.04	37.44	0	8

Table 3: STI infections that were not detected in home-based urine samples

*: a different in-house RT-PCR assay was used for CT, NG or MG

DC = delta cycle; Ct = Cycle threshold; NA = not applicable; Max = days between clinic visit and reception of the home-based sample at the laboratory

STI	DC value	Ct value in-house RT-PCR for CT, NG or MG*	Ct-value S-DiagMGTV RT-PCR (for information only)	Days between collection	Days of transport
CT	3.99	34.26	NA	1	2
CT	2.68	35.31	NA	1	6
CT	0.27	36.06	NA	6	4
NG	2.93	37.58	NA	8	4
NG	10.08	25.26	NA	2	6
MG	NA	31.28	Neg	Max 6	Max 6
MG	NA	31.96	40.51	1	2
MG	NA	28.66	34.67	Max 3	Max 3
MG	NA	34.58	38.50	9	4
MG	NA	34.23	Neg	1	5
MG	NA	32.04	38.14	Max 3	Max 3

Table 4: STI infections that were additionally detected in home-based urine samples

*: a different in-house RT-PCR assay was used for CT, NG or MG

DC = delta cycle; Ct = Cycle threshold; NA = not applicable; Max = days between clinic visit and reception of the home-based sample at the laboratory

Acceptability and user-friendliness of the Colli-Pee™ device

A total of 164 participants provided feedback regarding the use of the Colli-Pee™ device at baseline.

On a scale of one to five, 87.8% found that the Colli-Pee™ device was easy to very easy to use.

Instructions on how to send the Colli-Pee™ device were found to be easy by 90.2% of the participants.

Four participants found the Colli-Pee™ difficult to use (2.4%) and four other participants found it difficult to follow the instructions (2.4%). Likes from participants were: the ease of use (54.9%), no interruption of the urine flow (15.9%), hygienic (11.6%) and privacy of the home-based sample collection (11.0%); the dislikes were: nothing (47.0%), not being recyclable (14.6%), not hygienic (10.4%) and being too large (6.1%).

To the question of whether they would order an online STI test, 89.0% answered positively (146/164) and 91.1% (133/146) of those individuals would use the Colli-Pee™ device in that case. Six participants (4.1%) would not want to use the Colli-Pee™ device when ordering an online STI test. Participants were also asked how much they would pay for an online STI test with self-sampling. Price indications ranged from 0€ (10 participants) to 60€. Most of the participants (89/164) were willing to pay 10-20€.

DISCUSSION

Many studies have reported on male self-collected urine versus urethra clinician-collected sampling for STI screening, but 'real-world' studies, including sending of home-based urine samples for STI detection in men by post, are sparse.[4,5,20,21] In this study, we showed that the Colli-Pee™ collection device is a valuable and reliable method for collecting first-void urine for STI detection in MSM in Belgium, and that the collector can be shipped by regular post. Compared to the clinic-based sample, a total of three STIs (one CT and two MG infections) were not detected in the home-based sample. However, 11 additional infections were found in home-based samples collected with the Colli-

1
2
3 Pee™ device (3 CT, 2 NG and 6 MG infections). This high number of additional STIs could be explained
4
5 by the fact that first-void urine contains more DNA/RNA than mid-stream and, as a consequence,
6
7 should still be used for STI detection.[9] Indeed, we showed that using the Colli-Pee™ device first-void
8
9 urine was collected in a more standardized way compared to the clinic-based samples ($p < 0.001$).
10
11 Also, more human cells were collected in the home-based samples, however statistical significance
12
13 was lacking. The fact that participants could become positive during the time in between sampling
14
15 points is one of our main limitations and cannot be ignored. Preliminary data of the Be-PrEP-ared
16
17 study showed high incidence estimates after twelve months of the main Be-PrEP-ared study for
18
19 urethral CT/NG and MG: 11.5, 5.1 and 6.9 incidence rate per 100 person-years respectively.
20
21
22

23
24 Nevertheless, the most important observation is that only one Chlamydia positive result was missed.
25
26 The DC value of the Abbott assay performed on that clinic-based sample highlighted the low bacterial
27
28 load of that infection; in addition, transportation at room temperature for two days could have
29
30 induced DNA degradation.
31
32

33
34 The World Health Organisation (WHO) underlines the importance of integrating point-of-care assays
35
36 (POCTs) including innovative delivery options such as self-testing. [22] Unfortunately, to our
37
38 knowledge, current commercial POCTs for the most important STIs such as *Chlamydia trachomatis*
39
40 and *Neisseria gonorrhoeae* are still of sub-optimal quality and do not meet the ASSURED criteria that
41
42 were developed by the WHO STI Diagnostics Initiative.[22–25] A solution to the unavailability of
43
44 qualitative POCTs could be internet-accessed STI testing (e-STI testing) which is increasingly available
45
46 as an alternative to clinic testing all over the world.[26] E-STI testing includes postal self-sampling test
47
48 kits that are sent to a certified laboratory and web-based delivery of test results. Swab2Know, an
49
50 online HIV testing project confirmed that e-HIV testing is acceptable and feasible among MSM in
51
52 Belgium. [27] Commercial online self-sampling services for STIs are now emerging over the internet,
53
54 but evaluation of these services is lacking.
55
56
57
58
59
60

1
2
3 The present study is, however, subject to several limitations. Firstly, we only enrolled Be-PrEP-ared
4 participants and the participation level seriously declined during the study. As a result, our number of
5 CT/NG positives is quite low, which precludes firm conclusions. Secondly, as mentioned above, home-
6 based samples were not taken on the same day as clinic-based sampling and participants could have
7 become positive during that window period. We also do not know whether participants had urinated
8 one hour prior to collection. However, recent data show that the time between micturition is not
9 crucial for the detection of Chlamydia in men.[28] Thirdly, we did not monitor the temperature of the
10 transport of home-based samples which could also have an impact on the quality of the samples,
11 however, outside temperature between Oct 2015 and May 2018 varied between -10°C to 33°C with
12 an average of 11°C.
13
14
15
16
17
18
19
20
21
22
23
24
25

26 Fourthly, we cannot exclude specimen contamination, however, participants were instructed how to
27 correctly collect the clinic-based and home-based sample. Finally, reporting bias is also not to be
28 excluded. Not all participants who used a Colli-Pee™ device completed the survey, the additional
29 questions were included at the end of the lengthy main questionnaire of the Be-PrEP-ared study.
30
31
32
33
34
35

36 Besides PrEP users, e-STI testing has the potential to reach those who are most in need and a recent
37 study showed that some higher-risk groups, such as MSM, were more likely to use online services
38 [26,29]. Many studies have shown that home-based sampling is well accepted and, in fact, is the
39 preferred approach in these groups for STIs. Reasons for choosing home-based sampling were shorter
40 waiting times for results, convenience and less embarrassment. [30] Participants views regarding
41 ordering an online STI test in this study were very positive, 89% would like to order such a kit. The
42 Colli-Pee™ device was also found to be easy (90.2%) and although hygiene was one of the likes, it also
43 appeared in the dislikes, probably because the need to detach the collector manually can cause
44 leakage of urine. Participants were also concerned regarding possible ecological consequences,
45 although the plastic material is recyclable and can be incinerated into energy.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 We demonstrated that postal delivery of home-based collected urine does not influence STI detection
4 and can be used among PrEP users. Subsequently, PrEP users will be able to send first-void urine to
5 the laboratory with the Colli-Pee™ device one to two weeks before their routine PrEP follow up visit.
6
7 Results can then be discussed during the physician consultation and followed by treatment and future
8 antimicrobial testing if applicable, decreasing the number of physician visits. Decreasing the number
9 of face-to-face visits will lower the burden on staff workload and healthcare resources. However,
10 future economic evaluations will need to be conducted to prove this statement. E-STI testing could be
11 a promising approach in Belgium to reach patients in hard-to-reach populations and research on this
12 topic should be stimulated. Therefore, future studies to study the acceptability and impact of postal
13 shipment of home-collected material on the performance of STI assays requires additional
14 assessment.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 Figure legend: Fig 1: The Colli-Pee™ device instructions for use.
32

33 34 35 **ACKNOWLEDGEMENTS** 36 37 38

39 We would like to thank all the participants of the Be-PrEP-ared study who participated in this small
40 study. We also would like to thank Be-PrEP-ared study group but especially Maureen Aerts who was
41 crucial in the participation level of this study. Finally we would like to thank Wendy Thys for the data
42 entry.
43
44
45
46
47
48

49 50 **COMPETING INTERESTS STATEMENT** 51 52 53

54 The authors have no competing interests to declare.
55
56
57
58
59
60

FUNDING STATEMENT

This work was supported by Novosanis who provided the Colli-Pee™ devices and partially paid for the analyses performed on the home-based samples. In addition, a grant was obtained from the Flemish Agency for Innovation and Entrepreneurship to conduct the Be-PrEP-ared study.

DATASHARING STATEMENT

The data will be made publicly available except for the use and acceptability data as these will be retained at the Institute of Tropical Medicine (ITM), Antwerp due to ethical and privacy concerns. According to the ITM research data sharing policy, only fully anonymised data can be shared publicly. The data can however be made available after approval of a motivated and written request to the ITM at ITMresearchdataaccess@itg.be. The ITM data access committee will verify if the dataset is suitable for obtaining the study objective and assure that confidentiality and ethical requirements are in place.

CONTRIBUTORSHIP STATEMENT

IDB, TC, and BV designed the study. TR designed the acceptability survey. IDB performed the statistical analysis and wrote the first draft of the manuscript. HS, BDD, VC, SA performed testing. All authors read the final version of the manuscript and provided comments.

REFERENCES

- 1 WHO. Global Health Sector Strategy on Sexually Transmitted Infections 2016-2021. *World Heal Organ* 2016;**1**:63. doi:10.1055/s-2007-970201.
- 2 Lanjouw E, Ouburg S, de Vries H, *et al*. 2015 European guideline on the management of *Chlamydia trachomatis* infections. *Int J STD AIDS* 2016;**27**:333–48.

- 1
2
3 doi:10.1177/0956462415618837
4
5
6 3 Bignell C, Unemo M, Radcliffe K, *et al.* 2012 European guideline on the diagnosis and
7
8 treatment of gonorrhoea in adults. *Int J STD AIDS* 2013;**24**:85–92.
9
10 doi:10.1177/0956462412472837
11
12
13 4 Lunny C, Taylor D, Hoang L, *et al.* Self-Collected versus Clinician-Collected Sampling for
14
15 Chlamydia and Gonorrhoea Screening: A Systemic Review and Meta-Analysis. *PLoS One*
16
17 2015;**10**:e0132776. doi:10.1371/journal.pone.0132776
18
19
20
21 5 McNicol J, Debattista J. Use of the UriSwab collection device for testing of *Chlamydia*
22
23 *trachomatis* and *Neisseria gonorrhoeae* : implications for a postal testing service. *Int J STD*
24
25 *AIDS* 2013;**24**:477–80. doi:10.1177/0956462412472834
26
27
28 6 Vorsters A, Van den Bergh J, Micalessi I, *et al.* Optimization of HPV DNA detection in urine by
29
30 improving collection, storage, and extraction. *Eur J Clin Microbiol Infect Dis* 2014;**33**:2005–14.
31
32 doi:10.1007/s10096-014-2147-2
33
34
35 7 Theodorescu D, Schiffer E, Bauer HW, *et al.* Discovery and validation of urinary biomarkers for
36
37 prostate cancer. *Proteomics Clin Appl* 2008;**2**:556–70. doi:10.1002/prca.200780082
38
39
40 8 Wisniewski CA, White JA, Michel C-EC, *et al.* Optimal method of collection of first-void urine
41
42 for diagnosis of *Chlamydia trachomatis* infection in men. *J Clin Microbiol* 2008;**46**:1466–9.
43
44 doi:10.1128/JCM.02241-07
45
46
47 9 Johnson DJ, Calderaro AC, Roberts KA. Variation in Nuclear DNA Concentrations During
48
49 Urination. *J Forensic Sci* 2007;**52**:110–3. doi:10.1111/j.1556-4029.2006.00329.x
50
51
52
53 10 Traeger MW, Schroeder SE, Wright EJ, *et al.* Effects of Pre-exposure Prophylaxis for the
54
55 Prevention of Human Immunodeficiency Virus Infection on Sexual Risk Behavior in Men Who
56
57 Have Sex With Men: A Systematic Review and Meta-analysis. *Clin Infect Dis* Published Online
58
59 First: 2 March 2018. doi:10.1093/cid/ciy182
60

- 1
2
3 11 Kojima N, Davey DJ, Klausner JD. Pre-exposure prophylaxis for human immunodeficiency
4 virus and sexually transmitted infection acquisition among men who have sex with men. *AIDS*
5
6 Published Online First: 2016. doi:10.1097/QAD.0000000000001185
7
8
9
10
11 12 Salazar NAMEJ. EACS HIV guidelines 8.1. 2016.
12
13
14 13 WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection. *Geneva*
15
16 *World Heal Organ* Published Online First: 2017.[http://www.who.int/hiv/pub/prep/prep-](http://www.who.int/hiv/pub/prep/prep-implementation-tool/en/)
17
18 [implementation-tool/en/](http://www.who.int/hiv/pub/prep/prep-implementation-tool/en/) (accessed 21 Aug 2018).
19
20
21 14 De Baetselier I, Reyniers T, Nöstlinger C, *et al.* Pre-Exposure Prophylaxis (PrEP) as an
22
23 Additional Tool for HIV Prevention Among Men Who Have Sex With Men in Belgium: The Be-
24
25 PrEP-ared Study Protocol. *JMIR Res Protoc* 2017;**6**:e11. doi:10.2196/resprot.6767
26
27
28 15 Chen C-Y, Chi KH, Alexander S, *et al.* A real-time quadriplex PCR assay for the diagnosis of
29
30 rectal lymphogranuloma venereum and non-lymphogranuloma venereum Chlamydia
31
32 trachomatis infections. *Sex Transm Infect* 2008;**84**:273–6. doi:10.1136/sti.2007.029058
33
34
35 16 Hopkins MJ, Ashton LJ, Alloba F, *et al.* Validation of a laboratory-developed real-time PCR
36
37 protocol for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine. *Sex*
38
39 *Transm Infect* 2010;**86**:207–11. doi:10.1136/sti.2009.040634
40
41
42
43 17 Müller EE, Venter JME, Magooa MP, *et al.* Development of a rotor-gene real-time PCR assay
44
45 for the detection and quantification of Mycoplasma genitalium. *J Microbiol Methods*
46
47 2012;**88**:311–5. doi:10.1016/j.mimet.2011.12.017
48
49
50 18 Yuan CC, Miley W, Waters D. A quantification of human cells using an ERV-3 real time PCR
51
52 assay. *J Virol Methods* 2001;**91**:109–17.
53
54
55 19 Reyniers T, Nöstlinger C, Laga M, *et al.* Choosing between daily and event-driven Pre-
56
57 Exposure Prophylaxis: results of a Belgian PrEP demonstration project Conflict of Interest and
58
59 Source of Funding: A grant was obtained from the Flemish Agency for. *JAIDS J Acquir Immune*
60

- 1
2
3 *Defic Syndr Publ Ahead Print* doi:10.1097/QAI.0000000000001791
4
5
6 20 Morré SA, van Valkengoed IG, de Jong A, *et al.* Mailed, home-obtained urine specimens: a
7
8 reliable screening approach for detecting asymptomatic Chlamydia trachomatis infections. *J*
9
10 *Clin Microbiol* 1999;**37**:976–80.<http://www.ncbi.nlm.nih.gov/pubmed/10074512> (accessed
11
12 21 Aug 2018).
- 13
14
15 21 Fajardo-Bernal L, Aponte-Gonzalez J, Vigil P, *et al.* Home-based versus clinic-based specimen
16
17 collection in the management of Chlamydia trachomatis and Neisseria gonorrhoeae
18
19 infections. *Cochrane Database Syst Rev* 2015;:CD011317.
20
21 doi:10.1002/14651858.CD011317.pub2
22
23
24
25 22 Toskin I, Blondeel K, Peeling RW, *et al.* Advancing point of care diagnostics for the control and
26
27 prevention of STIs: the way forward. *Sex Transm Infect* 2017;**93**:S81–8. doi:10.1136/sextrans-
28
29 2016-053073
30
31
32
33 23 De Baetselier I, Mwambarangwe L, Cuylaerts V, *et al.* Evaluation of an enzymatic Chlamydia
34
35 trachomatis point-of-care rapid assay in Rwanda: the BioChekSwab Rapid Test. *Sex Transm*
36
37 *Infect* Published Online First: 16 October 2015. doi:10.1136/sextrans-2015-052202
38
39
40
41 24 Peeling RW, Holmes KK, Mabey D, *et al.* Rapid tests for sexually transmitted infections (STIs):
42
43 the way forward. *Sex Transm Infect* 2006;**82**:v1–6. doi:10.1136/sti.2006.024265
44
45
46 25 European Centre for Disease Prevention and Control. Novel approaches to testing for sexually
47
48 transmitted infections, including HIV and hepatitis B and C in Europe. Stockholm: 2012.
49
50 doi:10.2900/6481
51
52
53 26 Wilson E, Free C, Morris TP, *et al.* Internet-accessed sexually transmitted infection (e-STI)
54
55 testing and results service: A randomised, single-blind, controlled trial. *PLOS Med*
56
57 2017;**14**:e1002479. doi:10.1371/journal.pmed.1002479
58
59
60 27 Platteau T, Fransen K, Apers L, *et al.* Swab2know: An HIV-Testing Strategy Using Oral Fluid

- 1
2
3 Samples and Online Communication of Test Results for Men Who Have Sex With Men in
4
5 Belgium. *J Med Internet Res* 2015;**17**:e213. doi:10.2196/jmir.4384
6
7
8 28 Mathew T, O'Mahony C, Mallinson H. Shortening the voiding interval for men having
9
10 chlamydia nucleic acid amplification tests. *Int J STD AIDS* 2009;**20**:752–3.
11
12 doi:10.1258/ijisa.2009.009225
13
14
15 29 Barnard S, Free C, Bakolis I, *et al*. Comparing the characteristics of users of an online service
16
17 for STI self-sampling with clinic service users: a cross-sectional analysis. *Sex Transm Infect*
18
19 2018;;sextrans-2017-053302. doi:10.1136/sextrans-2017-053302
20
21
22
23 30 Paudyal P, Llewellyn C, Lau J, *et al*. Obtaining self-samples to diagnose curable sexually
24
25 transmitted infections: a systematic review of patients' experiences. *PLoS One*
26
27 2015;**10**:e0124310. doi:10.1371/journal.pone.0124310
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Fig 1: The Colli-Pee™ device instructions for use.

268x110mm (95 x 95 DPI)

Section & Topic	No	Item	Reported on page #
TITLE OR ABSTRACT			
	1	Identification as a study of diagnostic accuracy using at least one measure of accuracy (such as sensitivity, specificity, predictive values, or AUC)	2 (agreement was used as this is not a diagnostic study)
ABSTRACT			
	2	Structured summary of study design, methods, results, and conclusions (for specific guidance, see STARD for Abstracts)	2
INTRODUCTION			
	3	Scientific and clinical background, including the intended use and clinical role of the index test	3-4
	4	Study objectives and hypotheses	4
METHODS			
<i>Study design</i>	5	Whether data collection was planned before the index test and reference standard were performed (prospective study) or after (retrospective study)	5
<i>Participants</i>	6	Eligibility criteria	5
	7	On what basis potentially eligible participants were identified (such as symptoms, results from previous tests, inclusion in registry)	5-6
	8	Where and when potentially eligible participants were identified (setting, location and dates)	5
	9	Whether participants formed a consecutive, random or convenience series	5-6
<i>Test methods</i>	10a	Index test, in sufficient detail to allow replication	Not applicable same assay was used on both samples (but different kind of sample)
	10b	Reference standard, in sufficient detail to allow replication	Not applicable same assay was used on both samples (but different kind of sample)
	11	Rationale for choosing the reference standard (if alternatives exist)	Not applicable same assay was used on both samples (but different kind of sample)
	12a	Definition of and rationale for test positivity cut-offs or result categories of the index test, distinguishing pre-specified from exploratory	5-6
	12b	Definition of and rationale for test positivity cut-offs or result categories of the reference standard, distinguishing pre-specified from exploratory	5-6
	13a	Whether clinical information and reference standard results were available to the performers/readers of the index test	6
	13b	Whether clinical information and index test results were available to the assessors of the reference standard	6
<i>Analysis</i>	14	Methods for estimating or comparing measures of diagnostic accuracy	7
	15	How indeterminate index test or reference standard results were handled	6
	16	How missing data on the index test and reference standard were handled	Not applicable
	17	Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from exploratory	Not applicable
	18	Intended sample size and how it was determined	Not applicable
RESULTS			
<i>Participants</i>	19	Flow of participants, using a diagram	We did not include of flow of participants, however this has been discussed in the text p7-8

1		20	Baseline demographic and clinical characteristics of participants	7-8
2		21a	Distribution of severity of disease in those with the target condition	Not applicable
3		21b	Distribution of alternative diagnoses in those without the target condition	Not applicable
4		22	Time interval and any clinical interventions between index test and reference standard	8
5	<i>Test results</i>	23	Cross tabulation of the index test results (or their distribution) by the results of the reference standard	8
6		24	Estimates of diagnostic accuracy and their precision (such as 95% confidence intervals)	Cohen's kappa agreement was used p9
7		25	Any adverse events from performing the index test or the reference standard	Not applicable
8				
9				
10		25	Any adverse events from performing the index test or the reference standard	Not applicable
11	DISCUSSION			
12		26	Study limitations, including sources of potential bias, statistical uncertainty, and generalisability	13
13		27	Implications for practice, including the intended use and clinical role of the index test	13-14
14				
15	OTHER INFORMATION			
16				
17		28	Registration number and name of registry	6
18		29	Where the full study protocol can be accessed	Will be added as appendix
19		30	Sources of funding and other support; role of funders	15
20				
21				
22				
23				
24				
25				
26				
27				
28				
29				
30				
31				
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

STARD 2015

AIM

STARD stands for “Standards for Reporting Diagnostic accuracy studies”. This list of items was developed to contribute to the completeness and transparency of reporting of diagnostic accuracy studies. Authors can use the list to write informative study reports. Editors and peer-reviewers can use it to evaluate whether the information has been included in manuscripts submitted for publication.

EXPLANATION

A **diagnostic accuracy study** evaluates the ability of one or more medical tests to correctly classify study participants as having a **target condition**. This can be a disease, a disease stage, response or benefit from therapy, or an event or condition in the future. A medical test can be an imaging procedure, a laboratory test, elements from history and physical examination, a combination of these, or any other method for collecting information about the current health status of a patient.

The test whose accuracy is evaluated is called **index test**. A study can evaluate the accuracy of one or more index tests. Evaluating the ability of a medical test to correctly classify patients is typically done by comparing the distribution of the index test results with those of the **reference standard**. The reference standard is the best available method for establishing the presence or absence of the target condition. An accuracy study can rely on one or more reference standards.

If test results are categorized as either positive or negative, the cross tabulation of the index test results against those of the reference standard can be used to estimate the **sensitivity** of the index test (the proportion of participants *with* the target condition who have a positive index test), and its **specificity** (the proportion *without* the target condition who have a negative index test). From this cross tabulation (sometimes referred to as the contingency or “2x2” table), several other accuracy statistics can be estimated, such as the positive and negative **predictive values** of the test. Confidence intervals around estimates of accuracy can then be calculated to quantify the statistical **precision** of the measurements.

If the index test results can take more than two values, categorization of test results as positive or negative requires a **test positivity cut-off**. When multiple such cut-offs can be defined, authors can report a receiver operating characteristic (ROC) curve which graphically represents the combination of sensitivity and specificity for each possible test positivity cut-off. The **area under the ROC curve** informs in a single numerical value about the overall diagnostic accuracy of the index test.

The **intended use** of a medical test can be diagnosis, screening, staging, monitoring, surveillance, prediction or prognosis. The **clinical role** of a test explains its position relative to existing tests in the clinical pathway. A replacement test, for example, replaces an existing test. A triage test is used before an existing test; an add-on test is used after an existing test.

Besides diagnostic accuracy, several other outcomes and statistics may be relevant in the evaluation of medical tests. Medical tests can also be used to classify patients for purposes other than diagnosis, such as staging or prognosis. The STARD list was not explicitly developed for these other outcomes, statistics, and study types, although most STARD items would still apply.

DEVELOPMENT

This STARD list was released in 2015. The 30 items were identified by an international expert group of methodologists, researchers, and editors. The guiding principle in the development of STARD was to select items that, when reported, would help readers to judge the potential for bias in the study, to appraise the applicability of the study findings and the validity of conclusions and recommendations. The list represents an update of the first version, which was published in 2003.

More information can be found on <http://www.equator-network.org/reporting-guidelines/stard>.

